{"gene":"ADAM12","run_date":"2026-06-09T22:02:40","timeline":{"discoveries":[{"year":2002,"finding":"ADAM12 functions as the specific sheddase for HB-EGF in cardiomyocytes; dominant-negative ADAM12 expression abrogated GPCR-agonist-induced HB-EGF shedding and subsequent EGFR transactivation leading to cardiac hypertrophy. The inhibitor KB-R7785 was shown to bind directly to ADAM12.","method":"Dominant-negative expression, direct binding assay, in vivo mouse model of cardiac hypertrophy","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — dominant-negative functional rescue, direct binding demonstrated, replicated in vivo; multiple orthogonal methods in a focused study","pmids":["11786904"],"is_preprint":false},{"year":2000,"finding":"The disintegrin domains of ADAM12 (and ADAM15) interact specifically with integrin α9β1 in an RGD-independent manner, supporting cell-cell interaction.","method":"Recombinant domain binding assay, cell adhesion and cell-cell interaction assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted binding with recombinant disintegrin domain, functional cell adhesion validation, single lab with multiple orthogonal methods","pmids":["10944520"],"is_preprint":false},{"year":2003,"finding":"TGF-β induces ADAM12 expression in activated hepatic stellate cells via PI3K and MEK/ERK pathways; ADAM12 expression is up-regulated during the quiescent-to-activated transition of hepatic stellate cells.","method":"Northern blot, PI3K inhibitor (LY294002) and MEK inhibitor (UO126) treatment, rat/human HSC culture","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pathway inhibitor pharmacology, single lab, two inhibitors providing partial mechanistic support","pmids":["12717386"],"is_preprint":false},{"year":2002,"finding":"ADAM12 is N-glycosylated in the ER and proteolytically processed in the trans-Golgi network to an ~90 kDa mature form lacking the prodomain; the cytoplasmic domain regulates ER exit, and the prodomain α-helical region is required for proper folding and processing.","method":"Mutagenesis (L73P prodomain mutation), cell surface biotinylation, subcellular fractionation, Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with trafficking/processing biochemistry, multiple mutants tested in a single focused study","pmids":["12000744"],"is_preprint":false},{"year":2002,"finding":"ADAM12 cysteine-rich domain engages syndecan-4 as a primary receptor, triggering β1 integrin-dependent cell spreading, stress fiber assembly, and focal adhesion formation through a PKCα/RhoA signaling axis.","method":"Co-immunoprecipitation, PKC inhibitors, mutant syndecan-4 transfection, activated β1 integrin staining (12G10)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal signaling validated with dominant-negative mutants and pharmacological inhibitors, multiple orthogonal approaches in one study","pmids":["12509413"],"is_preprint":false},{"year":2003,"finding":"ADAM12 surface expression in preadipocytes forms complexes with β1 integrin (co-immunoprecipitation), impairs β1 integrin function, reorganizes actin stress fibers into a cortical network, reduces focal adhesions and fibronectin adhesion, and promotes apoptosis that can be rescued by β1-activating antibodies.","method":"Co-immunoprecipitation, retroviral transduction, immunostaining, Triton X-100 extraction, cell adhesion assays","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP plus functional rescue experiments, multiple orthogonal readouts, replicated with transient and stable expression","pmids":["12915587"],"is_preprint":false},{"year":2003,"finding":"PACSIN3, identified via yeast two-hybrid screening, binds the proline-rich region (aa 829–840) of ADAM12's cytoplasmic domain via its SH3 domain, and co-localizes with ADAM12; PACSIN3 overexpression enhances TPA-induced proHB-EGF shedding, while PACSIN3 siRNA knockdown attenuates it.","method":"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, co-localization, siRNA knockdown, ectodomain shedding assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — yeast two-hybrid plus GST pulldown plus co-IP plus functional shedding assay with both OE and KD, multiple orthogonal methods","pmids":["12952982"],"is_preprint":false},{"year":2004,"finding":"ADAM12 was found to be selectively overexpressed in glioblastomas and promotes cell proliferation through shedding of HB-EGF; ADAM inhibitor treatment reduced soluble HB-EGF in glioblastoma samples.","method":"Quantitative RT-PCR, in situ hybridization, immunoblotting, ADAM inhibitor treatment","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological inhibition of shedding in tissue context, correlative but with inhibitor functional experiment","pmids":["15509542"],"is_preprint":false},{"year":2004,"finding":"PKCε induces ADAM12 translocation to the cell surface, requiring catalytic activity of PKCε; both C1 and C2 domains of PKCε contain binding sites for ADAM12, and co-immunoprecipitation from membrane fractions confirmed the interaction.","method":"Co-immunoprecipitation, PMA treatment, myristoylated PKCε transfection, kinase-inactive mutant, cell surface immunostaining","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP plus kinase-dead mutant rescue plus gain-of-function, multiple orthogonal methods in one study","pmids":["15364951"],"is_preprint":false},{"year":2003,"finding":"ADAM12 expression level is higher in proliferating C2C12 myoblasts and reserve cells than in myotubes; siRNA knockdown of ADAM12 reduces expression of quiescence markers (p130, p27) and differentiation markers; overexpression of ADAM12 induces cell cycle arrest via upregulation of p130/p27 and downregulation of MyoD. The disintegrin-to-transmembrane region and cytoplasmic domain (but not metalloprotease domain) are required for ADAM12-mediated cell cycle arrest.","method":"siRNA knockdown, overexpression, domain deletion mutants, cell cycle analysis, Western blot","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA KD plus domain mutant dissection plus gain-of-function with defined phenotypic readouts","pmids":["12972593"],"is_preprint":false},{"year":2004,"finding":"ADAM12 and α9β1 integrin are co-expressed during human myogenic precursor cell (mpc) differentiation, co-immunoprecipitate, and their interaction (inhibited by ADAM12 antisense or anti-α9β1 antibody) accounts for ~47–48% of myotube fusion, particularly affecting formation of large myotubes.","method":"Co-immunoprecipitation, antisense oligonucleotides, blocking antibody, fusion quantification assay","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP plus two independent inhibition strategies (antisense + antibody) with quantitative fusion readout","pmids":["15574885"],"is_preprint":false},{"year":2006,"finding":"After furin cleavage of the ADAM12-S prodomain in the trans-Golgi, the ~25 kDa prodomain remains non-covalently associated with the ~68 kDa mature ADAM12-S. Electron microscopy revealed a compact clover-like four-domain structure for the full-length ADAM12-S molecule.","method":"Domain-specific antisera, immunoprecipitation, Western blot of serum and recombinant ADAM12, negative-stain electron microscopy","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural visualization by EM plus biochemical co-precipitation, single lab with multiple orthogonal methods","pmids":["16455653"],"is_preprint":false},{"year":2007,"finding":"ADAM12 interacts with TGF-β type II receptor (TβRII) and facilitates TGF-β signaling (Smad2 phosphorylation, Smad2/Smad4 association, transcriptional activation) independently of its protease activity; ADAM12 promotes accumulation of TβRII in early endosomes and stabilizes TβRII by suppressing its association with Smad7.","method":"Co-immunoprecipitation, dominant-negative and catalytically inactive ADAM12 mutants, endosomal fractionation, Smad reporter assay","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP plus protease-dead mutant plus endosomal fractionation plus transcriptional reporter, multiple orthogonal methods in a focused study","pmids":["17620406"],"is_preprint":false},{"year":2007,"finding":"Human ADAM12-S catalytic properties: cleavage of S-carboxymethylated transferrin at multiple sites; noncatalytic C-terminal domains regulate activity; N-TIMP-3 inhibits ADAM12-S with low nanomolar Ki; TIMP-2 inhibits with slightly lower affinity; TIMP-1 is a much weaker inhibitor; NaCl inhibits ADAM12.","method":"In vitro enzymatic assay with recombinant ADAM12-S and domain deletion mutants, kinetic analysis, N-terminal sequencing","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with recombinant protein and domain mutants, kinetic parameters established","pmids":["18081311"],"is_preprint":false},{"year":2008,"finding":"Heparan sulfate and heparin regulate ADAM12 activity through a prodomain/catalytic domain cationic molecular switch; endogenous cell surface proteoglycans also regulate this switch; human heparanase can promote ADAM12 sheddase activity at the cell surface by cleaving inhibitory heparan sulfate.","method":"In vitro sheddase assays, heparanase treatment, cell-based shedding assay, polyanion treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic reconstitution plus cell-based shedding assay with heparanase functional experiments","pmids":["18801731"],"is_preprint":false},{"year":2008,"finding":"RACK1 (receptor for activated PKC) was identified as an ADAM12 interacting protein by yeast two-hybrid; PKC-dependent phorbol ester treatment enhances co-immunoprecipitation of a ternary RACK1/ADAM12/PKC complex and ADAM12 membrane translocation; siRNA knockdown of RACK1 diminishes PMA-dependent ADAM12 membrane translocation in hepatic stellate cells.","method":"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, subcellular fractionation, phorbol ester stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — yeast two-hybrid plus co-IP of ternary complex plus siRNA functional validation with fractionation readout","pmids":["18621736"],"is_preprint":false},{"year":2004,"finding":"The disintegrin and cysteine-rich (DC) domains of ADAM12 bind integrin α7β1; α7X1 and α7X2 splice variants support equal adhesion to DC domain; adhesion to DC differs from laminin in Mn2+ requirements and does not trigger FAK Tyr397 phosphorylation or efficient spreading.","method":"Affinity column pulldown, cell adhesion assay, blocking antibody, FAK phosphorylation Western blot","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — affinity pulldown plus functional adhesion assay plus blocking antibody, single lab","pmids":["15242759"],"is_preprint":false},{"year":2005,"finding":"The intact extracellular domain of ADAM12 (metalloprotease + disintegrin/cysteine-rich domains together) supports myoblast-specific adhesion and spreading not mediated by β1 integrins or proteoglycans, and inhibits differentiation (reduces p21 and myogenin); neither the metalloprotease domain nor the disintegrin/cysteine-rich fragment alone recapitulates this activity, indicating cooperative interdomain interaction.","method":"Recombinant domain production in Drosophila S2 cells, cell adhesion/spreading assays, far-UV circular dichroism, Western blot for differentiation markers","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted domain interactions with structural (CD) and functional (adhesion, differentiation) validation, systematic domain dissection","pmids":["15849365"],"is_preprint":false},{"year":2005,"finding":"In cell adhesion assays, α9β1 integrin is the primary receptor for ADAM12; when α9β1 is absent, other β1 family integrins can serve as alternate receptors; the disintegrin domain alone supports only α9 integrin-dependent attachment, while full-length ADAM12 supports additional integrin-mediated attachment; cell spreading requires PI3K activity.","method":"Cell adhesion assays with recombinant ADAM12 fragments and mutants, blocking antibodies, PI3K inhibitor","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic domain fragments plus mutant plus pharmacological inhibition, single lab","pmids":["16061220"],"is_preprint":false},{"year":2005,"finding":"TGF-β1-induced ADAM12 expression in hepatic stellate cells requires both the PI3K/Frap-mTOR/p70S6K and MEK/ERK pathways; rapamycin (mTOR inhibitor) blocks p70S6K phosphorylation and ADAM12 induction, while basal ADAM12 expression depends on PI3K/Akt/GSK-3 signaling.","method":"PI3K inhibitor (LY294002), MEK inhibitor (UO126), rapamycin treatment, Western blot for phospho-p70S6K","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological pathway dissection with multiple inhibitors targeting distinct nodes, single lab","pmids":["16139919"],"is_preprint":false},{"year":2006,"finding":"ADAM12-S transgenic mice exhibit increased longitudinal bone growth through modulation of chondrocyte proliferation and maturation; mice expressing a truncated metalloprotease-deficient ADAM12-S showed no bone length alterations, indicating protease activity is required. ADAM12-S inhibits chondrocyte adhesion to fibronectin and collagen type II in vitro.","method":"Transgenic mouse bone length measurement, histology, BrdU incorporation, metalloprotease-deficient truncation mutant, in vitro chondrocyte adhesion assay","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic gain-of-function with catalytic mutant rescue experiment plus in vitro adhesion assay, multiple orthogonal readouts","pmids":["16869727"],"is_preprint":false},{"year":2009,"finding":"ADAM12-L co-localizes with c-Src at actin-rich peripheral structures; two separate c-Src binding sites in the ADAM12-L cytoplasmic tail interact with the SH3 domain of c-Src; c-Src kinase activity induces ADAM12-L tyrosine phosphorylation; the association is stabilized when c-Src kinase activity is disrupted; ADAM12-L enhances Src kinase activity upon integrin engagement.","method":"Co-immunoprecipitation, co-localization imaging, SH3 domain binding assay, kinase-inactive c-Src mutant, tyrosine phosphorylation Western blot","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP plus domain binding site mapping plus kinase-dead mutant plus kinase activity assay, multiple orthogonal methods","pmids":["19769962"],"is_preprint":false},{"year":2009,"finding":"MMP-7 controls transcription of ADAM12, forming a novel MMP-7/ADAM12 signaling axis in agonist-induced hypertension and cardiac hypertrophy; MMP-7 knockdown attenuates hypertension, inhibits ADAM12 overexpression, and prevents cardiac hypertrophy in mouse models.","method":"RNAi knockdown, antisense oligodeoxynucleotides, MMP-7 gene knockout, quantitative RT-PCR, rodent hypertension models","journal":"Circulation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three complementary approaches (pharmacological, RNAi, knockout) in vivo, single lab","pmids":["19398663"],"is_preprint":false},{"year":2010,"finding":"Antibody ligation of ADAM12 induces formation of invadopodia clusters with ECM-degrading capacity in cells expressing αvβ3 integrin and active c-Src; this requires an intact c-Src interaction site in the ADAM12 cytoplasmic domain but is independent of ADAM12 catalytic activity; caveolin-1 and MMP14/MT1-MMP localize in these clusters; ADAM12-mediated HB-EGF shedding occurs within invadopodia.","method":"Antibody ligation, invadopodia formation assay, domain mutants (cytoplasmic tail deletion, catalytic mutant), cholesterol depletion, ectodomain shedding assay","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — domain mutant dissection plus pharmacological manipulation plus functional shedding assay, multiple orthogonal methods","pmids":["20951132"],"is_preprint":false},{"year":2010,"finding":"TGF-β1 induces ADAM12 mRNA and protein in a Smad2/Smad3-dependent manner; SnoN, a negative regulator of TGF-β signaling, acts as a repressor of ADAM12 gene expression; SnoN overexpression reduces ADAM12 induction, while SnoN shRNA knockdown enhances it.","method":"Smad2/3-dependent reporter, shRNA knockdown of SnoN, overexpression of SnoN, Western blot, qRT-PCR","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — both gain- and loss-of-function for SnoN with Smad-pathway validation, single lab","pmids":["20457602"],"is_preprint":false},{"year":2010,"finding":"ADAM12 selectively inhibits ADAM12 activity; engineered N-TIMP-2 (with AB-loop removed) shows increased affinity for ADAM12 compared to TACE/ADAM17; N-TIMP-2 and its mutants inhibit the transmembrane ADAM12-L in cell-based HB-EGF shedding assays, revealing distinctive structural requirements for ADAM12 inhibition.","method":"Kinetic analysis with fluorescent peptide substrate, N-TIMP-2 mutagenesis, cell-based EGF shedding assay","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinetic assay plus mutagenesis plus cell-based functional validation in one study","pmids":["20533908"],"is_preprint":false},{"year":2011,"finding":"Notch signaling up-regulates ADAM12 expression in a CSL-dependent, IκB kinase-dependent manner; the microRNA-29 family mediates this effect by being downregulated by Notch, relieving repression of the ADAM12 3'UTR; in human cells, Notch specifically up-regulates ADAM12-L (which has a divergent 3'UTR containing the miR-29 site) but not ADAM12-S.","method":"Constitutively active Notch1 transfection, CSL reporter, IKK inhibitor, miR-29 target site validation, co-culture with Notch ligand-expressing cells, qRT-PCR","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple cell systems plus genetic and pharmacological inhibition plus miRNA target validation, multiple orthogonal methods","pmids":["21518768"],"is_preprint":false},{"year":2011,"finding":"Breast cancer-associated ADAM12 somatic mutations D301H and G479E (involving conserved residues) cause retention of ADAM12 in the ER, block cell surface trafficking, prevent Delta-like 1 shedding, and exert dominant-negative effects on wild-type ADAM12 processing.","method":"Mutagenesis, cell surface biotinylation, immunofluorescence, ectodomain shedding assay, dominant-negative co-expression","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 2 / Moderate — domain-specific mutations with trafficking, surface expression, and functional shedding readouts in multiple cell lines","pmids":["18241035"],"is_preprint":false},{"year":2013,"finding":"Notch signaling increases ADAM12 metalloprotease levels and activity in hypoxia in a Notch-dependent manner, leading to increased HB-EGF shedding, EGFR activation, and invadopodia formation; thus Notch-ADAM12-HB-EGF-EGFR constitutes a hypoxia-driven invasion signaling axis.","method":"Notch pathway inhibition, ADAM12 knockdown/overexpression, ectodomain shedding assay, invadopodia formation assay","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic pathway dissection with KD and OE experiments and functional shedding/invasion assays, single lab with multiple orthogonal methods","pmids":["23589494"],"is_preprint":false},{"year":2013,"finding":"ADAM12 redistributes endogenous MMP-14 to the cell surface and promotes its activation; subsequent gelatin degradation and reduced apoptosis depend on MMP-14 activity and cell surface αVβ3 integrin localization but not on ADAM12 catalytic activity or its cytoplasmic tail; a ternary ADAM12/αVβ3/MMP-14 complex is proposed based on co-localization and antibody inhibition.","method":"Co-localization, MMP-14 activity assays, specific monoclonal antibodies, domain mutants (catalytic-dead, cytoplasmic tail deletion), orthotopic implantation, Western blot for activated MMP-14","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain mutant dissection plus antibody inhibition plus in vivo tumor model with multiple orthogonal methods","pmids":["24006261"],"is_preprint":false},{"year":2013,"finding":"ADAM12 was identified by yeast two-hybrid as an EphA1-binding partner; ADAM12 enhances ephrin-A1 cleavage in response to TGF-β1 in primary tumors, releasing soluble ephrin-A1 into the serum that disrupts EphA1/ephrin-A1-mediated cell adhesion in the lungs, causing hyperpermeability and facilitating lung metastasis.","method":"Yeast two-hybrid, ectodomain cleavage assay (TGF-β1 stimulation), neutralizing antibody against soluble ephrin-A1, lung metastasis model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus functional cleavage assay plus in vivo neutralization, single lab","pmids":["23686306"],"is_preprint":false},{"year":2013,"finding":"ADAM12 screens positive for shedding of five new substrates: Kitl1, VE-cadherin, Flk-1, Tie-2, and VCAM-1; siRNA knockdown of ADAM12 reduces cytokine-induced VE-cadherin shedding in endothelial cells.","method":"Ectodomain shedding screen, siRNA knockdown, Western blot of shed forms","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — shedding screen plus siRNA knockdown with defined substrate readouts, single lab","pmids":["23458101"],"is_preprint":false},{"year":2012,"finding":"ILK (integrin-linked kinase) was identified as a new ADAM12L interacting protein; ADAM12L co-immunoprecipitates with ILK via its cytoplasmic tail; in hepatic stellate cells, ADAM12L and ILK redistribute to focal adhesions upon β1 integrin stimulation; ADAM12L upregulation activates Akt Ser-473 phosphorylation via PI3K/ILK in a protease-independent manner; ILK depletion abolishes this survival signal.","method":"Co-immunoprecipitation, siRNA knockdown of ILK and ADAM12L, cytoplasmic tail deletion mutant, Akt phosphorylation Western blot, ILK kinase activity assay from immunoprecipitates","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP plus domain mutant plus ILK activity assay plus siRNA rescue experiments with Akt readout","pmids":["22767580"],"is_preprint":false},{"year":2015,"finding":"ADAM12 mediates ectodomain shedding of E-cadherin to promote trophoblast fusion; siRNA knockdown of ADAM12 impedes spontaneous cytotrophoblast fusion; overexpression of ADAM12S potentiates fusion in Bewo cells; E-cadherin is identified as a novel ADAM12 substrate; ADAM12 expression is under transcriptional control of protein kinase A.","method":"siRNA knockdown, ADAM12S overexpression, E-cadherin shedding assay, PKA inhibitor, two distinct trophoblast fusion models","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function plus gain-of-function plus substrate identification, two independent cell models","pmids":["25909890"],"is_preprint":false},{"year":2015,"finding":"ADAM12L (but not ADAM12S) induces EMT in MCF10A cells independently of proteolytic activity but requiring the cytoplasmic tail; ADAM12L-dependent EMT involves increased phosphorylation of Smad3, Akt, and ERK; TGF-β receptor or ERK inhibition reverses ADAM12L-induced mesenchymal phenotype.","method":"ADAM12L overexpression (catalytic mutant, cytoplasmic tail deletion), Western blot for EMT markers and phospho-signaling, TGF-β receptor inhibitor, ERK inhibitor","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Moderate — systematic domain mutant analysis plus pharmacological rescue in a defined cell model with multiple EMT/signaling readouts","pmids":["26407179"],"is_preprint":false},{"year":2015,"finding":"miR-29b/c and miR-200b/c directly target the ADAM12-L 3'UTR (but not ADAM12-S 3'UTR) to reduce ADAM12-L mRNA and protein levels; mutation of miR-29b/c or miR-200b/c target sequences in the ADAM12-L 3'UTR abrogates this repression; miR-30b/d did not show consistent effects.","method":"miRNA mimic transfection, 3'UTR luciferase reporter assay with target site mutations, metabolic labeling for translation rate, miRNA hairpin inhibitors, qRT-PCR","journal":"BMC cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — luciferase reporter with target site mutagenesis plus endogenous miRNA inhibitor experiments plus metabolic labeling, multiple orthogonal methods","pmids":["25886595"],"is_preprint":false},{"year":2015,"finding":"ADAM12 expression in endothelial cells regulates the neural vascular barrier under hypoxia by mediating shedding of claudin-5 (tight junction molecule); inhibition of ADAM12 (or ADAM17) metalloprotease activity rescues claudin-5 membrane localization and barrier function both in vitro and in vivo under hypoxia.","method":"Metalloprotease inhibition, ADAM12 and ADAM17 specific knockdown, in vitro barrier assay (TEER), in vivo neural vascular barrier assessment","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gene-specific knockdown plus pharmacological inhibition with functional barrier readouts in vitro and in vivo, single lab","pmids":["26242473"],"is_preprint":false},{"year":2005,"finding":"ADAM12 protease activity and the FISH adapter protein mediate Aβ-induced neuronal death; expression of a protease-deficient ADAM12 mutant blocks Aβ-induced neuronal death; the C-terminal FISH fragment induces cell death that requires ADAM12 metalloprotease activity; Aβ treatment and toxic FISH fragment both induce accumulation of an ADAM12 N-terminal cleavage product, indicating ADAM12 sheddase activation.","method":"Protease-deficient ADAM12 mutant expression, FISH domain truncation expression, conditioned medium analysis for ADAM12 cleavage products, neuronal cell death assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — protease-dead mutant rescue plus substrate cleavage product detection, single lab with functional and biochemical readouts","pmids":["15710903"],"is_preprint":false},{"year":2017,"finding":"Twist1 transcription factor induces ADAM12 expression; ADAM12 knockdown blocks Twist1-induced tumor invasion and metastasis in breast xenografts without affecting primary tumor formation; both the disintegrin and metalloproteinase domains are required for invadopodia function, while the metalloproteinase domain is dispensable for focal adhesion turnover; ADAM12 knockdown inhibits focal adhesion turnover (shown by live-imaging).","method":"siRNA/shRNA knockdown, 3D organoid invasion assay, xenograft metastasis model, live-imaging of focal adhesion turnover, domain mutant analysis","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain mutant dissection plus live imaging plus in vivo xenograft, multiple orthogonal methods across in vitro and in vivo settings","pmids":["28468988"],"is_preprint":false},{"year":2019,"finding":"ADAM12 interacts with basigin and cleaves it in the juxtamembrane region; ADAM12 overexpression increases ectodomain shedding of an alkaline phosphatase-tagged basigin reporter; CRISPR/Cas9 knockout of ADAM12 reduces basigin shedding, which is rescued by ADAM12 re-expression; ADAM12-generated basigin ectodomain fragments were detected in conditioned media and serum samples.","method":"Co-immunoprecipitation, alkaline phosphatase shedding reporter, CRISPR/Cas9 knockout, rescue by re-expression, Western blot for endogenous ectodomain fragments in conditioned media and serum","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR knockout plus rescue plus shedding reporter plus endogenous substrate fragment detection, multiple orthogonal methods","pmids":["31013576"],"is_preprint":false},{"year":2021,"finding":"Hypoxia activates HIF-dependent ADAM12 expression in breast cancer cells, which mediates increased HB-EGF ectodomain shedding, EGFR activation, and FAK phosphorylation; ADAM12 inhibition decreased hypoxia-induced cell migration/invasion in vitro and dramatically impaired lung metastasis in orthotopic mouse models.","method":"HIF knockdown/overexpression, ADAM12 siRNA, ectodomain shedding assay, EGFR/FAK phosphorylation Western blot, orthotopic breast cancer metastasis model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic pathway dissection (HIF→ADAM12→HB-EGF→EGFR→FAK) in vitro with in vivo metastasis validation, multiple orthogonal methods","pmids":["33952697"],"is_preprint":false},{"year":2020,"finding":"ADAM12 acts as a T-cell costimulatory molecule expressed on naïve T cells; ADAM12 Fab antibody stimulation amplifies TCR signaling to promote T-bet-mediated IFNγ production and Th1 differentiation; genomic ADAM12 loss or T-cell ADAM12 knockdown selectively diminishes T-bet and IFNγ in Th1 cells without affecting Th17 cells; ADAM12-/- mice show profoundly reduced Th1-mediated neuroinflammation in EAE.","method":"Monoclonal ADAM12 Fab antibody stimulation, ADAM12 knockout mice, shRNA knockdown in T cells, EAE model, transcriptomic profiling, IFNγ/T-bet measurement","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — antibody functional assay plus KO mice plus shRNA with multiple lineage-specific and in vivo readouts","pmids":["32572163"],"is_preprint":false},{"year":2005,"finding":"FLRG (follistatin-related gene) directly interacts with the cysteine-rich domain of ADAM12 as identified by yeast two-hybrid; FLRG inhibits osteoclast differentiation from murine spleen cells and RAW264.7 macrophages, reducing osteoclast numbers and nuclei count.","method":"Yeast two-hybrid, osteoclast differentiation assay with recombinant FLRG, RANKL/M-CSF stimulation","journal":"Biology of the cell","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid without biochemical co-IP validation; functional assay with recombinant FLRG tests FLRG function rather than directly validating ADAM12 role","pmids":["15574124"],"is_preprint":false},{"year":2005,"finding":"TGF-β induces ADAM12 gene expression through PI3K/Frap-mTOR/p70S6K and MEK/ERK pathways in hepatic stellate cells. Inhibition of p70S6K by rapamycin blocks TGF-β-dependent ADAM12 expression.","method":"Rapamycin, LY294002, UO126 treatment; p70S6K phosphorylation Western blot; TGF-β1 stimulation","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — three pharmacological inhibitors targeting distinct pathway nodes with phospho-signaling readouts, single lab","pmids":["16139919"],"is_preprint":false}],"current_model":"ADAM12 is a multidomain transmembrane or secreted metalloprotease (ADAM12-L and ADAM12-S isoforms) that undergoes furin-mediated prodomain cleavage in the trans-Golgi to yield a constitutively active ~90 kDa mature form whose cell-surface translocation is regulated by PKCε (via RACK1 and direct PKCε binding); the retained prodomain forms a non-covalent clover-like structure with the mature enzyme and its sheddase activity is allosterically regulated by a heparan sulfate/prodomain molecular switch; at the cell surface ADAM12 sheds multiple EGFR ligands (notably HB-EGF), E-cadherin, basigin, ephrin-A1, VE-cadherin, Tie-2, and VCAM-1 to drive EGFR/ERK/FAK signaling, and its shedding activity is inhibited by TIMP-3 and engineered N-TIMP-2 but not TIMP-1; ADAM12 also interacts non-catalytically with TGF-β type II receptor to promote Smad2 signaling and TβRII endosomal trafficking, with ILK via its cytoplasmic tail to activate PI3K/Akt survival signaling, with c-Src (via cytoplasmic SH3-binding sites) to regulate Src kinase activity and subcellular redistribution, and with integrins α9β1, α7β1, and αvβ3 via its disintegrin/cysteine-rich domains to modulate cell adhesion, actin cytoskeleton organization, and focal adhesion turnover; upstream, ADAM12 expression is transcriptionally induced by TGF-β1 (via Smad2/3, derepression of SnoN, and PI3K/mTOR/p70S6K), Notch (via CSL/IKK, partly through suppression of miR-29), HIF (in hypoxia), Twist1, and HER2/PI3K/AKT, and post-transcriptionally repressed by miR-29 and miR-200 families targeting the ADAM12-L 3'UTR; together these activities enable ADAM12 to regulate myoblast fusion, adipocyte differentiation, chondrocyte proliferation, trophoblast invasion and fusion, Th1 T-cell costimulation, and tumor invasion/metastasis."},"narrative":{"mechanistic_narrative":"ADAM12 is a multidomain metalloprotease (transmembrane ADAM12-L and secreted ADAM12-S isoforms) that couples regulated ectodomain shedding to integrin- and adapter-mediated signaling to drive cell fusion, differentiation, adhesion remodeling, and tumor invasion [PMID:11786904, PMID:15574885, PMID:28468988]. The enzyme is N-glycosylated in the ER and proteolytically matured in the trans-Golgi to an ~90 kDa form; its cytoplasmic domain governs ER exit and the prodomain α-helix is required for folding and processing, after which the cleaved prodomain remains non-covalently bound to mature enzyme in a compact clover-like four-domain structure [PMID:12000744, PMID:16455653]. Mature ADAM12 sheds a broad substrate set — HB-EGF, E-cadherin, basigin, ephrin-A1, claudin-5, and endothelial junction/receptor molecules including VE-cadherin and Tie-2 — to transactivate EGFR and remodel cell–cell barriers [PMID:11786904, PMID:25909890, PMID:31013576, PMID:23686306, PMID:26242473, PMID:23458101]. Catalytic activity is intrinsically inhibitable by N-TIMP-3 and TIMP-2 (but weakly by TIMP-1) and is allosterically gated by a heparan sulfate/prodomain cationic molecular switch that heparanase can relieve at the cell surface [PMID:18081311, PMID:18801731]. Surface delivery of the active enzyme is controlled by PKCε acting through direct binding and the RACK1 scaffold, with PACSIN3 coupling the cytoplasmic tail to shedding [PMID:15364951, PMID:18621736, PMID:12952982]. Beyond proteolysis, ADAM12 signals non-catalytically: it binds TβRII to promote Smad2 signaling and receptor endosomal trafficking [PMID:17620406], engages ILK through its cytoplasmic tail to activate PI3K/Akt survival signaling [PMID:22767580], associates with c-Src and αvβ3 integrin to assemble MMP-14-containing invadopodia and drive focal adhesion turnover [PMID:19769962, PMID:20951132, PMID:24006261, PMID:28468988], and uses its disintegrin/cysteine-rich domains to bind integrins α9β1 and α7β1 and syndecan-4, organizing actin, focal adhesions, and cell spreading [PMID:10944520, PMID:15242759, PMID:12509413]. These activities underpin myoblast cell-cycle exit and fusion, chondrocyte proliferation during bone growth, trophoblast fusion, and Th1 T-cell costimulation, and they are amplified in cancer through hypoxia/HIF-, Notch-, Twist1-, and TGF-β/Smad-driven induction with post-transcriptional repression by miR-29 and miR-200 on the ADAM12-L 3'UTR [PMID:12972593, PMID:15574885, PMID:16869727, PMID:25909890, PMID:32572163, PMID:33952697, PMID:23589494, PMID:28468988, PMID:20457602, PMID:25886595].","teleology":[{"year":2000,"claim":"Established that ADAM12's disintegrin domain mediates integrin-based cell-cell interaction, defining a non-proteolytic adhesive function distinct from canonical RGD-dependent binding.","evidence":"Recombinant disintegrin domain binding and cell adhesion assays with integrin α9β1","pmids":["10944520"],"confidence":"High","gaps":["Did not map the binding interface residues","In vivo relevance of α9β1 engagement not addressed"]},{"year":2002,"claim":"Identified ADAM12 as a specific physiological HB-EGF sheddase driving EGFR transactivation, linking the protease to GPCR-evoked cardiac hypertrophy in vivo.","evidence":"Dominant-negative expression, direct inhibitor binding, mouse cardiac hypertrophy model","pmids":["11786904"],"confidence":"High","gaps":["Substrate repertoire beyond HB-EGF not addressed","Did not resolve how shedding is spatially restricted"]},{"year":2002,"claim":"Defined the biosynthetic route of ADAM12, showing furin-type trans-Golgi maturation and that the cytoplasmic tail and prodomain α-helix control trafficking and folding.","evidence":"Prodomain/cytoplasmic mutagenesis, surface biotinylation, subcellular fractionation","pmids":["12000744"],"confidence":"High","gaps":["Did not identify the maturation protease directly","Trafficking machinery for ER exit not defined"]},{"year":2002,"claim":"Connected ADAM12 to outside-in adhesion signaling by showing syndecan-4 acts as a receptor triggering β1-integrin-dependent spreading via PKCα/RhoA.","evidence":"Co-IP, PKC inhibitors, mutant syndecan-4, activated β1 integrin staining","pmids":["12509413"],"confidence":"High","gaps":["Direct syndecan-4/ADAM12 binding stoichiometry not resolved","Link to proteolytic function unaddressed"]},{"year":2003,"claim":"Showed ADAM12 controls myoblast fate, with expression promoting cell-cycle arrest and quiescence markers via its disintegrin/cytoplasmic regions rather than its protease domain.","evidence":"siRNA, domain-deletion overexpression, cell cycle analysis in C2C12","pmids":["12972593"],"confidence":"High","gaps":["Receptor mediating the non-proteolytic effect not defined here","Downstream effectors of p130/p27 induction unclear"]},{"year":2003,"claim":"Revealed that surface ADAM12 antagonizes β1 integrin function in preadipocytes, remodeling actin and promoting apoptosis rescuable by integrin activation.","evidence":"Co-IP, retroviral expression, adhesion assays, integrin-activating antibody rescue","pmids":["12915587"],"confidence":"High","gaps":["Molecular basis of integrin impairment not resolved","Relationship to adipocyte differentiation in vivo untested"]},{"year":2003,"claim":"Identified PACSIN3 as a cytoplasmic-tail SH3 partner that couples ADAM12 to regulated proHB-EGF shedding.","evidence":"Yeast two-hybrid, GST pulldown, co-IP, siRNA, shedding assay","pmids":["12952982"],"confidence":"High","gaps":["Mechanism by which PACSIN3 enhances shedding not defined","Endogenous physiological context limited"]},{"year":2003,"claim":"Placed ADAM12 transcription downstream of TGF-β via PI3K and MEK/ERK during hepatic stellate cell activation.","evidence":"Northern blot with PI3K and MEK inhibitors in HSC culture","pmids":["12717386"],"confidence":"Medium","gaps":["Inhibitor-based pharmacology only, no genetic confirmation","Transcription factors not identified at this stage"]},{"year":2004,"claim":"Showed PKCε directly drives ADAM12 surface translocation, defining a kinase-dependent regulatory step controlling protease availability.","evidence":"Co-IP, PMA, myristoylated and kinase-dead PKCε mutants, surface immunostaining","pmids":["15364951"],"confidence":"High","gaps":["Phosphorylation site mediating translocation not mapped","Did not yet implicate a scaffold"]},{"year":2004,"claim":"Demonstrated ADAM12 overexpression and HB-EGF shedding promote glioblastoma proliferation, extending the sheddase axis to tumor growth.","evidence":"qRT-PCR, in situ hybridization, ADAM inhibitor treatment of tumor tissue","pmids":["15509542"],"confidence":"Medium","gaps":["Correlative tissue data with non-specific ADAM inhibitor","ADAM12-specific requirement not genetically isolated"]},{"year":2004,"claim":"Quantified ADAM12/α9β1 integrin interaction as a major driver of human myoblast fusion, particularly large myotube formation.","evidence":"Co-IP, antisense, anti-α9β1 blocking antibody, fusion quantification","pmids":["15574885"],"confidence":"High","gaps":["The fusion machinery downstream of α9β1 engagement not defined","Residual fusion (~50%) involves unidentified factors"]},{"year":2004,"claim":"Expanded the integrin partner set by showing the disintegrin/cysteine-rich domains bind α7β1 with adhesion properties distinct from laminin.","evidence":"Affinity pulldown, adhesion assay, blocking antibody, FAK phospho-blot","pmids":["15242759"],"confidence":"Medium","gaps":["Functional consequence of α7β1 binding in vivo unclear","Single-lab adhesion characterization"]},{"year":2005,"claim":"Defined cooperative interdomain function, showing the intact extracellular region supports myoblast adhesion and inhibits differentiation in a manner no single domain reproduces.","evidence":"Recombinant domains from S2 cells, adhesion/spreading assays, CD spectroscopy, differentiation markers","pmids":["15849365"],"confidence":"High","gaps":["The myoblast receptor for intact ectodomain not identified","Structural basis of cooperativity not resolved"]},{"year":2005,"claim":"Refined the integrin receptor hierarchy, establishing α9β1 as primary with alternate β1 integrins as backups and PI3K dependence for spreading.","evidence":"Adhesion assays with ADAM12 fragments/mutants, blocking antibodies, PI3K inhibitor","pmids":["16061220"],"confidence":"Medium","gaps":["Single-lab in vitro adhesion model","Selectivity rules among β1 integrins not fully defined"]},{"year":2005,"claim":"Linked ADAM12 protease activity to Aβ-induced neuronal death through the FISH adapter, implicating sheddase activation in neurotoxicity.","evidence":"Protease-dead mutant, FISH truncation, cleavage-product detection, neuronal death assay","pmids":["15710903"],"confidence":"Medium","gaps":["Relevant shed substrate driving death not identified","Single-lab functional model"]},{"year":2005,"claim":"Dissected the TGF-β-driven induction cascade, showing both PI3K/mTOR/p70S6K and MEK/ERK branches are required for ADAM12 expression.","evidence":"Rapamycin, LY294002, UO126, phospho-p70S6K blots in HSCs","pmids":["16139919"],"confidence":"Medium","gaps":["Pharmacology-only with no genetic confirmation","Transcription factor endpoints not identified here"]},{"year":2005,"claim":"Identified FLRG as a cysteine-rich-domain partner linked to osteoclast differentiation, though the assay primarily tested FLRG rather than ADAM12.","evidence":"Yeast two-hybrid, osteoclast differentiation assay with recombinant FLRG","pmids":["15574124"],"confidence":"Low","gaps":["Awaits biochemical co-IP validation of the interaction","ADAM12's direct role in osteoclastogenesis not tested"]},{"year":2006,"claim":"Demonstrated in vivo that ADAM12-S protease activity promotes longitudinal bone growth by modulating chondrocyte proliferation and adhesion.","evidence":"Transgenic mice, BrdU, catalytically dead truncation, chondrocyte adhesion assays","pmids":["16869727"],"confidence":"High","gaps":["The chondrocyte substrate cleaved was not identified","Mechanism of adhesion inhibition unresolved"]},{"year":2006,"claim":"Established the architecture of the mature/prodomain complex, showing retained non-covalent prodomain association and a compact clover-like structure.","evidence":"Domain-specific antisera, immunoprecipitation, negative-stain EM","pmids":["16455653"],"confidence":"High","gaps":["High-resolution structure not obtained","Functional role of retained prodomain in activity not defined here"]},{"year":2007,"claim":"Revealed a protease-independent signaling role: ADAM12 binds TβRII to enhance Smad2 signaling and stabilize the receptor in endosomes by blocking Smad7.","evidence":"Co-IP, catalytically dead mutants, endosomal fractionation, Smad reporter","pmids":["17620406"],"confidence":"High","gaps":["Direct binding interface on TβRII not mapped","Generality across TGF-β-responsive cell types untested"]},{"year":2007,"claim":"Characterized ADAM12-S catalytic mechanism, defined noncatalytic C-terminal regulation, and established the TIMP inhibition profile (N-TIMP-3 > TIMP-2 >> TIMP-1).","evidence":"In vitro kinetics with recombinant protein and domain mutants, N-terminal sequencing","pmids":["18081311"],"confidence":"High","gaps":["Physiological substrate specificity not addressed","Structural basis of TIMP selectivity unresolved"]},{"year":2008,"claim":"Uncovered an allosteric heparan sulfate/prodomain cationic switch regulating sheddase activity, relieved by heparanase at the cell surface.","evidence":"In vitro sheddase assays, heparanase and polyanion treatment, cell-based shedding","pmids":["18801731"],"confidence":"High","gaps":["Switch residues not fully mapped","In vivo contribution of proteoglycan regulation untested"]},{"year":2008,"claim":"Identified RACK1 as the scaffold assembling a RACK1/ADAM12/PKC ternary complex required for PKC-dependent membrane translocation.","evidence":"Yeast two-hybrid, co-IP of ternary complex, siRNA, fractionation","pmids":["18621736"],"confidence":"High","gaps":["RACK1 binding site on ADAM12 not mapped","Quantitative contribution to surface pool not defined"]},{"year":2009,"claim":"Defined a reciprocal ADAM12-L/c-Src relationship in which two cytoplasmic SH3-binding sites recruit Src and ADAM12 enhances Src activity upon integrin engagement.","evidence":"Co-IP, colocalization, SH3 binding, kinase-dead Src, tyrosine phospho-blot","pmids":["19769962"],"confidence":"High","gaps":["Functional consequence of ADAM12 tyrosine phosphorylation unclear","Downstream Src targets not defined here"]},{"year":2009,"claim":"Identified an MMP-7/ADAM12 transcriptional axis in agonist-induced hypertension and cardiac hypertrophy in vivo.","evidence":"RNAi, antisense, MMP-7 knockout, qRT-PCR, rodent hypertension models","pmids":["19398663"],"confidence":"Medium","gaps":["Mechanism by which MMP-7 controls ADAM12 transcription unresolved","Single-lab in vivo correlation"]},{"year":2010,"claim":"Mapped a non-catalytic invadopodia function requiring the c-Src interaction site, αvβ3 integrin, and recruitment of caveolin-1 and MT1-MMP.","evidence":"Antibody ligation, domain mutants, cholesterol depletion, shedding assay","pmids":["20951132"],"confidence":"High","gaps":["Physiological ligand triggering invadopodia not identified","Order of assembly of the cluster unresolved"]},{"year":2010,"claim":"Placed SnoN as a Smad-dependent repressor whose derepression mediates TGF-β1 induction of ADAM12, refining the transcriptional logic.","evidence":"Smad2/3 reporter, SnoN shRNA and overexpression, qRT-PCR, Western blot","pmids":["20457602"],"confidence":"Medium","gaps":["Direct promoter occupancy not shown","Single-lab cell context"]},{"year":2010,"claim":"Engineered N-TIMP-2 variants showing ADAM12 has distinctive structural inhibition requirements, providing selective inhibitor leads.","evidence":"Kinetics with fluorescent peptide, N-TIMP-2 mutagenesis, cell-based shedding","pmids":["20533908"],"confidence":"High","gaps":["Co-crystal structure of inhibitor complex not obtained","In vivo efficacy untested"]},{"year":2011,"claim":"Defined a Notch→miR-29 circuit that isoform-selectively up-regulates ADAM12-L through CSL/IKK signaling and relief of 3'UTR repression.","evidence":"Active Notch1, CSL reporter, IKK inhibitor, miR-29 target validation, qRT-PCR","pmids":["21518768"],"confidence":"High","gaps":["Direct Notch target gene driving miR-29 suppression unclear","Physiological setting limited"]},{"year":2011,"claim":"Showed cancer-associated D301H/G479E mutations cause ER retention, block surface trafficking and Delta-like 1 shedding, and act dominant-negatively.","evidence":"Mutagenesis, surface biotinylation, immunofluorescence, shedding and dominant-negative assays","pmids":["18241035"],"confidence":"High","gaps":["Functional consequence of loss-of-trafficking in tumors untested","Whether mutations are drivers unresolved"]},{"year":2012,"claim":"Identified ILK as a cytoplasmic-tail partner mediating protease-independent PI3K/ILK/Akt survival signaling and focal adhesion redistribution.","evidence":"Co-IP, siRNA, tail-deletion mutant, Akt phospho-blot, ILK kinase assay","pmids":["22767580"],"confidence":"High","gaps":["ILK binding motif on ADAM12 tail not mapped","Survival phenotype in vivo untested"]},{"year":2013,"claim":"Demonstrated ADAM12 redistributes and activates MMP-14 within an αvβ3-dependent complex to degrade ECM and reduce apoptosis, independent of its own catalysis.","evidence":"Colocalization, MMP-14 activity assays, antibodies, domain mutants, orthotopic implantation","pmids":["24006261"],"confidence":"High","gaps":["Direct ternary complex not biochemically isolated","Mechanism of MMP-14 activation unresolved"]},{"year":2013,"claim":"Connected ADAM12 to metastatic niche permeability via TGF-β1-stimulated ephrin-A1 shedding that disrupts EphA1/ephrin-A1 adhesion in lung.","evidence":"Yeast two-hybrid, cleavage assay, neutralizing antibody, lung metastasis model","pmids":["23686306"],"confidence":"Medium","gaps":["Direct ADAM12 cleavage of ephrin-A1 vs indirect not fully resolved","Single-lab in vivo model"]},{"year":2013,"claim":"Expanded the substrate repertoire to endothelial junction and receptor proteins (VE-cadherin, Tie-2, Flk-1, VCAM-1, Kitl1) in cytokine-driven shedding.","evidence":"Shedding screen, siRNA, Western blot of shed forms","pmids":["23458101"],"confidence":"Medium","gaps":["Direct vs indirect cleavage not distinguished for all hits","Physiological context limited to endothelial cells"]},{"year":2013,"claim":"Established a hypoxia-driven Notch-ADAM12-HB-EGF-EGFR invasion axis controlling invadopodia formation.","evidence":"Notch inhibition, ADAM12 KD/OE, shedding and invadopodia assays","pmids":["23589494"],"confidence":"High","gaps":["How hypoxia couples to Notch in this axis not fully resolved","In vivo metastasis not tested in this study"]},{"year":2015,"claim":"Identified E-cadherin as a substrate whose shedding by ADAM12 promotes trophoblast fusion under PKA transcriptional control.","evidence":"siRNA, ADAM12S overexpression, E-cadherin shedding, PKA inhibitor, two fusion models","pmids":["25909890"],"confidence":"High","gaps":["Whether E-cadherin shedding alone is sufficient for fusion unclear","PKA-responsive promoter elements not mapped"]},{"year":2015,"claim":"Showed ADAM12-L induces EMT via the cytoplasmic tail and Smad3/Akt/ERK signaling independent of protease activity, distinguishing isoform functions.","evidence":"Domain mutant overexpression, EMT/phospho-signaling blots, TβR and ERK inhibitors","pmids":["26407179"],"confidence":"High","gaps":["Direct tail effector linking to Smad3 unidentified","Single cell-line model"]},{"year":2015,"claim":"Defined isoform-selective post-transcriptional control, with miR-29b/c and miR-200b/c directly repressing the ADAM12-L 3'UTR.","evidence":"miRNA mimics, 3'UTR luciferase with mutated sites, metabolic labeling, miRNA inhibitors","pmids":["25886595"],"confidence":"High","gaps":["Relative dominance of each miRNA in vivo unclear","Upstream control of these miRNAs in tumors not addressed here"]},{"year":2015,"claim":"Linked ADAM12 to neural vascular barrier regulation via claudin-5 shedding under hypoxia.","evidence":"Metalloprotease inhibition, ADAM12/ADAM17 knockdown, TEER, in vivo barrier assay","pmids":["26242473"],"confidence":"Medium","gaps":["Overlapping ADAM17 contribution not fully separated","Direct claudin-5 cleavage not biochemically proven"]},{"year":2017,"claim":"Placed ADAM12 downstream of Twist1 as a required effector of invasion/metastasis, with distinct domain requirements for invadopodia versus focal adhesion turnover.","evidence":"Knockdown, 3D organoid invasion, xenograft metastasis, live-imaging, domain mutants","pmids":["28468988"],"confidence":"High","gaps":["Twist1 direct binding to ADAM12 promoter not shown","Mechanism coupling domains to adhesion turnover unresolved"]},{"year":2019,"claim":"Validated basigin as a direct ADAM12 substrate using CRISPR knockout and rescue, with detectable endogenous shed fragments.","evidence":"Co-IP, AP shedding reporter, CRISPR KO and re-expression, endogenous fragment detection","pmids":["31013576"],"confidence":"High","gaps":["Functional consequence of basigin shedding not addressed","Physiological trigger of cleavage unclear"]},{"year":2020,"claim":"Revealed a non-classical immune role: ADAM12 is a T-cell costimulatory molecule selectively driving T-bet/IFNγ Th1 differentiation and Th1-mediated neuroinflammation.","evidence":"Fab antibody stimulation, knockout mice, shRNA, EAE model, transcriptomics","pmids":["32572163"],"confidence":"High","gaps":["Receptor/ligand mediating costimulation not identified","Whether protease activity is involved unclear"]},{"year":2021,"claim":"Established a HIF→ADAM12→HB-EGF→EGFR→FAK hypoxia axis driving breast cancer migration and lung metastasis in vivo.","evidence":"HIF KD/OE, ADAM12 siRNA, shedding and phospho-EGFR/FAK blots, orthotopic metastasis model","pmids":["33952697"],"confidence":"High","gaps":["Direct HIF binding to ADAM12 promoter not shown here","Contribution of other shed substrates to metastasis unresolved"]},{"year":null,"claim":"How the diverse non-catalytic scaffolding functions (TβRII, ILK, c-Src, integrins) are integrated with regulated proteolysis to produce context-specific outputs, and the receptors mediating ADAM12's adhesive and immune-costimulatory roles, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of the active enzyme-prodomain complex with bound substrate","Receptor mediating T-cell costimulation unidentified","Coordination between shedding and adapter signaling in a single cell context not reconstituted"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,13,33,39,31]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,13,14]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[1,4,16,10]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[4,5,21]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[12,41]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[12,32,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,5,8,23]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[3,27]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[3,11]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[12]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[11,30,39]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[4,5,21,23]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,12,32,21,40]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,28,38,40,27]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9,10,20,33]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,3,13,33,39]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[4,16,20,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[41]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[24,26,35,38]}],"complexes":["RACK1/ADAM12/PKCε ternary complex","ADAM12/αvβ3/MMP-14 invadopodial complex"],"partners":["ITGA9","PKCΕ","RACK1","PACSIN3","TGFBR2","ILK","SRC","SDC4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O43184","full_name":"Disintegrin and metalloproteinase domain-containing protein 12","aliases":["Meltrin-alpha"],"length_aa":909,"mass_kda":99.5,"function":"Involved in skeletal muscle regeneration, specifically at the onset of cell fusion. Also involved in macrophage-derived giant cells (MGC) and osteoclast formation from mononuclear precursors (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O43184/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADAM12","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADAM12","total_profiled":1310},"omim":[{"mim_id":"619455","title":"SH3 AND PX DOMAINS-CONTAINING PROTEIN 2A; SH3PXD2A","url":"https://www.omim.org/entry/619455"},{"mim_id":"610783","title":"MICRO RNA 29B1; MIR29B1","url":"https://www.omim.org/entry/610783"},{"mim_id":"607114","title":"A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 33; ADAM33","url":"https://www.omim.org/entry/607114"},{"mim_id":"605548","title":"A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 15; ADAM15","url":"https://www.omim.org/entry/605548"},{"mim_id":"603640","title":"A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 19; ADAM19","url":"https://www.omim.org/entry/603640"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"placenta","ntpm":126.8}],"url":"https://www.proteinatlas.org/search/ADAM12"},"hgnc":{"alias_symbol":["MCMPMltna","MLTN"],"prev_symbol":[]},"alphafold":{"accession":"O43184","domains":[{"cath_id":"-","chopping":"42-89_115-173","consensus_level":"medium","plddt":81.3349,"start":42,"end":173},{"cath_id":"-","chopping":"513-656","consensus_level":"high","plddt":85.7284,"start":513,"end":656}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O43184","model_url":"https://alphafold.ebi.ac.uk/files/AF-O43184-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O43184-F1-predicted_aligned_error_v6.png","plddt_mean":72.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADAM12","jax_strain_url":"https://www.jax.org/strain/search?query=ADAM12"},"sequence":{"accession":"O43184","fasta_url":"https://rest.uniprot.org/uniprotkb/O43184.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O43184/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O43184"}},"corpus_meta":[{"pmid":"11786904","id":"PMC_11786904","title":"Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.","date":"2002","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11786904","citation_count":606,"is_preprint":false},{"pmid":"22842476","id":"PMC_22842476","title":"Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22842476","citation_count":344,"is_preprint":false},{"pmid":"10944520","id":"PMC_10944520","title":"RGD-independent binding of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10944520","citation_count":183,"is_preprint":false},{"pmid":"12717386","id":"PMC_12717386","title":"ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling.","date":"2003","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12717386","citation_count":180,"is_preprint":false},{"pmid":"18342566","id":"PMC_18342566","title":"Cellular roles of ADAM12 in health and disease.","date":"2008","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18342566","citation_count":165,"is_preprint":false},{"pmid":"15586220","id":"PMC_15586220","title":"The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer.","date":"2005","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15586220","citation_count":147,"is_preprint":false},{"pmid":"15509542","id":"PMC_15509542","title":"ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15509542","citation_count":127,"is_preprint":false},{"pmid":"15930294","id":"PMC_15930294","title":"A role for ADAM12 in breast tumor progression and stromal cell apoptosis.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15930294","citation_count":125,"is_preprint":false},{"pmid":"23589494","id":"PMC_23589494","title":"Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia.","date":"2013","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23589494","citation_count":120,"is_preprint":false},{"pmid":"12915587","id":"PMC_12915587","title":"ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function.","date":"2003","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/12915587","citation_count":117,"is_preprint":false},{"pmid":"17278174","id":"PMC_17278174","title":"First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system.","date":"2007","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/17278174","citation_count":117,"is_preprint":false},{"pmid":"17189408","id":"PMC_17189408","title":"Molecular profiling of ADAM12 in human bladder cancer.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17189408","citation_count":104,"is_preprint":false},{"pmid":"15994630","id":"PMC_15994630","title":"Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia.","date":"2005","source":"Obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/15994630","citation_count":102,"is_preprint":false},{"pmid":"12509413","id":"PMC_12509413","title":"ADAM12/syndecan-4 signaling promotes beta 1 integrin-dependent cell spreading through protein kinase Calpha and RhoA.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12509413","citation_count":100,"is_preprint":false},{"pmid":"17620406","id":"PMC_17620406","title":"The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor.","date":"2007","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17620406","citation_count":100,"is_preprint":false},{"pmid":"9622634","id":"PMC_9622634","title":"Spatially- and temporally-restricted expression of meltrin alpha (ADAM12) and beta (ADAM19) in mouse embryo.","date":"1998","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/9622634","citation_count":90,"is_preprint":false},{"pmid":"16607276","id":"PMC_16607276","title":"ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16607276","citation_count":86,"is_preprint":false},{"pmid":"14691998","id":"PMC_14691998","title":"ADAM12: a novel first-trimester maternal serum marker for Down syndrome.","date":"2003","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/14691998","citation_count":86,"is_preprint":false},{"pmid":"15574885","id":"PMC_15574885","title":"ADAM12 and alpha9beta1 integrin are instrumental in human myogenic cell differentiation.","date":"2004","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15574885","citation_count":77,"is_preprint":false},{"pmid":"33952697","id":"PMC_33952697","title":"Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33952697","citation_count":76,"is_preprint":false},{"pmid":"12952982","id":"PMC_12952982","title":"PACSIN3 binds ADAM12/meltrin alpha and up-regulates ectodomain shedding of heparin-binding epidermal growth factor-like growth factor.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12952982","citation_count":74,"is_preprint":false},{"pmid":"19398663","id":"PMC_19398663","title":"Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy.","date":"2009","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/19398663","citation_count":66,"is_preprint":false},{"pmid":"30042416","id":"PMC_30042416","title":"Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30042416","citation_count":63,"is_preprint":false},{"pmid":"23686306","id":"PMC_23686306","title":"ADAM12-cleaved ephrin-A1 contributes to lung metastasis.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23686306","citation_count":62,"is_preprint":false},{"pmid":"15364951","id":"PMC_15364951","title":"Regulation of ADAM12 cell-surface expression by protein kinase C epsilon.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15364951","citation_count":61,"is_preprint":false},{"pmid":"29136943","id":"PMC_29136943","title":"ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29136943","citation_count":61,"is_preprint":false},{"pmid":"21493715","id":"PMC_21493715","title":"ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21493715","citation_count":58,"is_preprint":false},{"pmid":"18978109","id":"PMC_18978109","title":"First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome.","date":"2008","source":"Obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/18978109","citation_count":57,"is_preprint":false},{"pmid":"23680494","id":"PMC_23680494","title":"A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23680494","citation_count":55,"is_preprint":false},{"pmid":"12000744","id":"PMC_12000744","title":"Intracellular processing of metalloprotease disintegrin ADAM12.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12000744","citation_count":53,"is_preprint":false},{"pmid":"24006261","id":"PMC_24006261","title":"ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/24006261","citation_count":52,"is_preprint":false},{"pmid":"18081311","id":"PMC_18081311","title":"Catalytic properties of ADAM12 and its domain deletion mutants.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18081311","citation_count":52,"is_preprint":false},{"pmid":"16139919","id":"PMC_16139919","title":"Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells.","date":"2005","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/16139919","citation_count":52,"is_preprint":false},{"pmid":"12972593","id":"PMC_12972593","title":"Role of metalloprotease disintegrin ADAM12 in determination of quiescent reserve cells during myogenic differentiation in vitro.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12972593","citation_count":52,"is_preprint":false},{"pmid":"16455653","id":"PMC_16455653","title":"ADAM12 is a four-leafed clover: the excised prodomain remains bound to the mature enzyme.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16455653","citation_count":51,"is_preprint":false},{"pmid":"25909890","id":"PMC_25909890","title":"ADAM12-directed ectodomain shedding of E-cadherin potentiates trophoblast fusion.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/25909890","citation_count":50,"is_preprint":false},{"pmid":"28148288","id":"PMC_28148288","title":"Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28148288","citation_count":49,"is_preprint":false},{"pmid":"19003798","id":"PMC_19003798","title":"First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in prediction of small-for-gestational-age fetuses.","date":"2008","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/19003798","citation_count":49,"is_preprint":false},{"pmid":"23458101","id":"PMC_23458101","title":"ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23458101","citation_count":47,"is_preprint":false},{"pmid":"23491141","id":"PMC_23491141","title":"Polymorphic variation within the ADAMTS2, ADAMTS14, ADAMTS5, ADAM12 and TIMP2 genes and the risk of Achilles tendon pathology: a genetic association study.","date":"2013","source":"Journal of science and medicine in sport","url":"https://pubmed.ncbi.nlm.nih.gov/23491141","citation_count":47,"is_preprint":false},{"pmid":"28765266","id":"PMC_28765266","title":"ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28765266","citation_count":46,"is_preprint":false},{"pmid":"25591790","id":"PMC_25591790","title":"Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer.","date":"2015","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/25591790","citation_count":46,"is_preprint":false},{"pmid":"27252423","id":"PMC_27252423","title":"Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis.","date":"2016","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/27252423","citation_count":46,"is_preprint":false},{"pmid":"30442938","id":"PMC_30442938","title":"ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.","date":"2018","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30442938","citation_count":45,"is_preprint":false},{"pmid":"18621736","id":"PMC_18621736","title":"RACK1, a new ADAM12 interacting protein. Contribution to liver fibrogenesis.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18621736","citation_count":43,"is_preprint":false},{"pmid":"28468988","id":"PMC_28468988","title":"ADAM12 induction by Twist1 promotes tumor invasion and metastasis via regulation of invadopodia and focal adhesions.","date":"2017","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/28468988","citation_count":42,"is_preprint":false},{"pmid":"26407179","id":"PMC_26407179","title":"The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26407179","citation_count":42,"is_preprint":false},{"pmid":"32019179","id":"PMC_32019179","title":"ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32019179","citation_count":42,"is_preprint":false},{"pmid":"21875931","id":"PMC_21875931","title":"ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression.","date":"2011","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/21875931","citation_count":42,"is_preprint":false},{"pmid":"18604515","id":"PMC_18604515","title":"ADAM12: a potential target for the treatment of chronic wounds.","date":"2008","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/18604515","citation_count":42,"is_preprint":false},{"pmid":"21986939","id":"PMC_21986939","title":"A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21986939","citation_count":41,"is_preprint":false},{"pmid":"23135915","id":"PMC_23135915","title":"Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross-talk between MeCP2 and NF1 transcription factor family.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23135915","citation_count":41,"is_preprint":false},{"pmid":"15710903","id":"PMC_15710903","title":"Amyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activity.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15710903","citation_count":40,"is_preprint":false},{"pmid":"16869727","id":"PMC_16869727","title":"ADAM12-S stimulates bone growth in transgenic mice by modulating chondrocyte proliferation and maturation.","date":"2006","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/16869727","citation_count":38,"is_preprint":false},{"pmid":"19601832","id":"PMC_19601832","title":"Targeting ADAM12 in human disease: head, body or tail?","date":"2009","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/19601832","citation_count":37,"is_preprint":false},{"pmid":"25886595","id":"PMC_25886595","title":"ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25886595","citation_count":37,"is_preprint":false},{"pmid":"27144841","id":"PMC_27144841","title":"Metalloproteinases ADAM12 and MMP-14 are associated with cavernous sinus invasion in pituitary adenomas.","date":"2016","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27144841","citation_count":37,"is_preprint":false},{"pmid":"26163448","id":"PMC_26163448","title":"ADAM12: a genetic modifier of preclinical peripheral arterial disease.","date":"2015","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26163448","citation_count":36,"is_preprint":false},{"pmid":"29476791","id":"PMC_29476791","title":"An ADAM12 and FAK positive feedback loop amplifies the interaction signal of tumor cells with extracellular matrix to promote esophageal cancer metastasis.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29476791","citation_count":36,"is_preprint":false},{"pmid":"22284607","id":"PMC_22284607","title":"Genetic association analysis of GDF5 and ADAM12 for knee osteoarthritis.","date":"2012","source":"Joint bone spine","url":"https://pubmed.ncbi.nlm.nih.gov/22284607","citation_count":36,"is_preprint":false},{"pmid":"18801731","id":"PMC_18801731","title":"Heparan sulfate regulates ADAM12 through a molecular switch mechanism.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18801731","citation_count":35,"is_preprint":false},{"pmid":"20951132","id":"PMC_20951132","title":"Extracellular engagement of ADAM12 induces clusters of invadopodia with localized ectodomain shedding activity.","date":"2010","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20951132","citation_count":35,"is_preprint":false},{"pmid":"20533908","id":"PMC_20533908","title":"Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2).","date":"2010","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/20533908","citation_count":35,"is_preprint":false},{"pmid":"21518768","id":"PMC_21518768","title":"Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21518768","citation_count":34,"is_preprint":false},{"pmid":"15242759","id":"PMC_15242759","title":"Interaction of the disintegrin and cysteine-rich domains of ADAM12 with integrin alpha7beta1.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15242759","citation_count":33,"is_preprint":false},{"pmid":"19769962","id":"PMC_19769962","title":"ADAM12 localizes with c-Src to actin-rich structures at the cell periphery and regulates Src kinase activity.","date":"2009","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19769962","citation_count":33,"is_preprint":false},{"pmid":"24243624","id":"PMC_24243624","title":"A disintegrin and metalloproteinase 12 (ADAM12) localizes to invasive trophoblast, promotes cell invasion and directs column outgrowth in early placental development.","date":"2013","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/24243624","citation_count":32,"is_preprint":false},{"pmid":"20176000","id":"PMC_20176000","title":"ADAM12 is expressed by astrocytes during experimental demyelination.","date":"2010","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/20176000","citation_count":30,"is_preprint":false},{"pmid":"19040574","id":"PMC_19040574","title":"The metalloproteinase ADAM-12 regulates bronchial epithelial cell proliferation and apoptosis.","date":"2008","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/19040574","citation_count":30,"is_preprint":false},{"pmid":"20457602","id":"PMC_20457602","title":"The role of SnoN in transforming growth factor beta1-induced expression of metalloprotease-disintegrin ADAM12.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20457602","citation_count":30,"is_preprint":false},{"pmid":"12456779","id":"PMC_12456779","title":"The expression of ADAM12 (meltrin alpha) in human giant cell tumours of bone.","date":"2002","source":"Molecular pathology : MP","url":"https://pubmed.ncbi.nlm.nih.gov/12456779","citation_count":29,"is_preprint":false},{"pmid":"21387162","id":"PMC_21387162","title":"ADAM12 induces estrogen-independence in breast cancer cells.","date":"2011","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/21387162","citation_count":29,"is_preprint":false},{"pmid":"24695627","id":"PMC_24695627","title":"Extravillous trophoblast-associated ADAM12 exerts pro-invasive properties, including induction of integrin beta 1-mediated cellular spreading.","date":"2014","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/24695627","citation_count":29,"is_preprint":false},{"pmid":"17982130","id":"PMC_17982130","title":"Transgenic overexpression of ADAM12 suppresses muscle regeneration and aggravates dystrophy in aged mdx mice.","date":"2007","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17982130","citation_count":29,"is_preprint":false},{"pmid":"16061220","id":"PMC_16061220","title":"Hierarchy of ADAM12 binding to integrins in tumor cells.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16061220","citation_count":28,"is_preprint":false},{"pmid":"18241035","id":"PMC_18241035","title":"Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein.","date":"2008","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18241035","citation_count":28,"is_preprint":false},{"pmid":"36717944","id":"PMC_36717944","title":"ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36717944","citation_count":27,"is_preprint":false},{"pmid":"19609547","id":"PMC_19609547","title":"Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma.","date":"2009","source":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19609547","citation_count":27,"is_preprint":false},{"pmid":"24402778","id":"PMC_24402778","title":"Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity.","date":"2013","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24402778","citation_count":25,"is_preprint":false},{"pmid":"26242473","id":"PMC_26242473","title":"ADAM12 and ADAM17 are essential molecules for hypoxia-induced impairment of neural vascular barrier function.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26242473","citation_count":25,"is_preprint":false},{"pmid":"23578941","id":"PMC_23578941","title":"The ADAM12 is upregulated in synovitis and postinflammatory fibrosis of the synovial membrane in patients with early radiographic osteoarthritis.","date":"2013","source":"Joint bone spine","url":"https://pubmed.ncbi.nlm.nih.gov/23578941","citation_count":25,"is_preprint":false},{"pmid":"22015022","id":"PMC_22015022","title":"The secretion of PAPP-A, ADAM12, and PP13 correlates with the size of the placenta for the first month of pregnancy.","date":"2011","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/22015022","citation_count":24,"is_preprint":false},{"pmid":"26477568","id":"PMC_26477568","title":"Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26477568","citation_count":23,"is_preprint":false},{"pmid":"16213489","id":"PMC_16213489","title":"ADAM12-mediated focal adhesion formation is differently regulated by beta1 and beta3 integrins.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/16213489","citation_count":23,"is_preprint":false},{"pmid":"17440933","id":"PMC_17440933","title":"Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease.","date":"2007","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17440933","citation_count":23,"is_preprint":false},{"pmid":"23771733","id":"PMC_23771733","title":"Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype.","date":"2013","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/23771733","citation_count":23,"is_preprint":false},{"pmid":"22767580","id":"PMC_22767580","title":"Identification of ILK as a new partner of the ADAM12 disintegrin and metalloprotease in cell adhesion and survival.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22767580","citation_count":22,"is_preprint":false},{"pmid":"15574124","id":"PMC_15574124","title":"FLRG, a new ADAM12-associated protein, modulates osteoclast differentiation.","date":"2005","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15574124","citation_count":22,"is_preprint":false},{"pmid":"32572163","id":"PMC_32572163","title":"ADAM12 is a costimulatory molecule that determines Th1 cell fate and mediates tissue inflammation.","date":"2020","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32572163","citation_count":21,"is_preprint":false},{"pmid":"31013576","id":"PMC_31013576","title":"Identification of ADAM12 as a Novel Basigin Sheddase.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31013576","citation_count":21,"is_preprint":false},{"pmid":"25139103","id":"PMC_25139103","title":"EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25139103","citation_count":21,"is_preprint":false},{"pmid":"22540429","id":"PMC_22540429","title":"Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis.","date":"2012","source":"Journal of the European Academy of Dermatology and Venereology : JEADV","url":"https://pubmed.ncbi.nlm.nih.gov/22540429","citation_count":21,"is_preprint":false},{"pmid":"22847849","id":"PMC_22847849","title":"First-trimester prediction of preterm birth using ADAM12, PAPP-A, uterine artery Doppler, and maternal characteristics.","date":"2012","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/22847849","citation_count":21,"is_preprint":false},{"pmid":"26417939","id":"PMC_26417939","title":"ADAM12 and PAPP-A: Candidate regulators of trophoblast invasion and first trimester markers of healthy trophoblasts.","date":"2015","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/26417939","citation_count":20,"is_preprint":false},{"pmid":"28852196","id":"PMC_28852196","title":"ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28852196","citation_count":19,"is_preprint":false},{"pmid":"26503019","id":"PMC_26503019","title":"Expression of ADAM12 is regulated by E2F1 in small cell lung cancer.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26503019","citation_count":18,"is_preprint":false},{"pmid":"28395594","id":"PMC_28395594","title":"Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.","date":"2017","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/28395594","citation_count":17,"is_preprint":false},{"pmid":"22267082","id":"PMC_22267082","title":"Upregulated expression of ADAM12 is associated with progression of oral squamous cell carcinoma.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22267082","citation_count":17,"is_preprint":false},{"pmid":"19841944","id":"PMC_19841944","title":"Adam12 plays a role during uterine decidualization in mice.","date":"2009","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/19841944","citation_count":17,"is_preprint":false},{"pmid":"15849365","id":"PMC_15849365","title":"Cooperation of the metalloprotease, disintegrin, and cysteine-rich domains of ADAM12 during inhibition of myogenic differentiation.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15849365","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52488,"output_tokens":11134,"usd":0.162237,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22327,"output_tokens":10603,"usd":0.188355,"stage2_stop_reason":"end_turn"},"total_usd":0.350592,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"ADAM12 functions as the specific sheddase for HB-EGF in cardiomyocytes; dominant-negative ADAM12 expression abrogated GPCR-agonist-induced HB-EGF shedding and subsequent EGFR transactivation leading to cardiac hypertrophy. The inhibitor KB-R7785 was shown to bind directly to ADAM12.\",\n      \"method\": \"Dominant-negative expression, direct binding assay, in vivo mouse model of cardiac hypertrophy\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dominant-negative functional rescue, direct binding demonstrated, replicated in vivo; multiple orthogonal methods in a focused study\",\n      \"pmids\": [\"11786904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The disintegrin domains of ADAM12 (and ADAM15) interact specifically with integrin α9β1 in an RGD-independent manner, supporting cell-cell interaction.\",\n      \"method\": \"Recombinant domain binding assay, cell adhesion and cell-cell interaction assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted binding with recombinant disintegrin domain, functional cell adhesion validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"10944520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TGF-β induces ADAM12 expression in activated hepatic stellate cells via PI3K and MEK/ERK pathways; ADAM12 expression is up-regulated during the quiescent-to-activated transition of hepatic stellate cells.\",\n      \"method\": \"Northern blot, PI3K inhibitor (LY294002) and MEK inhibitor (UO126) treatment, rat/human HSC culture\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pathway inhibitor pharmacology, single lab, two inhibitors providing partial mechanistic support\",\n      \"pmids\": [\"12717386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ADAM12 is N-glycosylated in the ER and proteolytically processed in the trans-Golgi network to an ~90 kDa mature form lacking the prodomain; the cytoplasmic domain regulates ER exit, and the prodomain α-helical region is required for proper folding and processing.\",\n      \"method\": \"Mutagenesis (L73P prodomain mutation), cell surface biotinylation, subcellular fractionation, Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with trafficking/processing biochemistry, multiple mutants tested in a single focused study\",\n      \"pmids\": [\"12000744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ADAM12 cysteine-rich domain engages syndecan-4 as a primary receptor, triggering β1 integrin-dependent cell spreading, stress fiber assembly, and focal adhesion formation through a PKCα/RhoA signaling axis.\",\n      \"method\": \"Co-immunoprecipitation, PKC inhibitors, mutant syndecan-4 transfection, activated β1 integrin staining (12G10)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal signaling validated with dominant-negative mutants and pharmacological inhibitors, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"12509413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ADAM12 surface expression in preadipocytes forms complexes with β1 integrin (co-immunoprecipitation), impairs β1 integrin function, reorganizes actin stress fibers into a cortical network, reduces focal adhesions and fibronectin adhesion, and promotes apoptosis that can be rescued by β1-activating antibodies.\",\n      \"method\": \"Co-immunoprecipitation, retroviral transduction, immunostaining, Triton X-100 extraction, cell adhesion assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP plus functional rescue experiments, multiple orthogonal readouts, replicated with transient and stable expression\",\n      \"pmids\": [\"12915587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PACSIN3, identified via yeast two-hybrid screening, binds the proline-rich region (aa 829–840) of ADAM12's cytoplasmic domain via its SH3 domain, and co-localizes with ADAM12; PACSIN3 overexpression enhances TPA-induced proHB-EGF shedding, while PACSIN3 siRNA knockdown attenuates it.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, co-localization, siRNA knockdown, ectodomain shedding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — yeast two-hybrid plus GST pulldown plus co-IP plus functional shedding assay with both OE and KD, multiple orthogonal methods\",\n      \"pmids\": [\"12952982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ADAM12 was found to be selectively overexpressed in glioblastomas and promotes cell proliferation through shedding of HB-EGF; ADAM inhibitor treatment reduced soluble HB-EGF in glioblastoma samples.\",\n      \"method\": \"Quantitative RT-PCR, in situ hybridization, immunoblotting, ADAM inhibitor treatment\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological inhibition of shedding in tissue context, correlative but with inhibitor functional experiment\",\n      \"pmids\": [\"15509542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PKCε induces ADAM12 translocation to the cell surface, requiring catalytic activity of PKCε; both C1 and C2 domains of PKCε contain binding sites for ADAM12, and co-immunoprecipitation from membrane fractions confirmed the interaction.\",\n      \"method\": \"Co-immunoprecipitation, PMA treatment, myristoylated PKCε transfection, kinase-inactive mutant, cell surface immunostaining\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus kinase-dead mutant rescue plus gain-of-function, multiple orthogonal methods in one study\",\n      \"pmids\": [\"15364951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ADAM12 expression level is higher in proliferating C2C12 myoblasts and reserve cells than in myotubes; siRNA knockdown of ADAM12 reduces expression of quiescence markers (p130, p27) and differentiation markers; overexpression of ADAM12 induces cell cycle arrest via upregulation of p130/p27 and downregulation of MyoD. The disintegrin-to-transmembrane region and cytoplasmic domain (but not metalloprotease domain) are required for ADAM12-mediated cell cycle arrest.\",\n      \"method\": \"siRNA knockdown, overexpression, domain deletion mutants, cell cycle analysis, Western blot\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA KD plus domain mutant dissection plus gain-of-function with defined phenotypic readouts\",\n      \"pmids\": [\"12972593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ADAM12 and α9β1 integrin are co-expressed during human myogenic precursor cell (mpc) differentiation, co-immunoprecipitate, and their interaction (inhibited by ADAM12 antisense or anti-α9β1 antibody) accounts for ~47–48% of myotube fusion, particularly affecting formation of large myotubes.\",\n      \"method\": \"Co-immunoprecipitation, antisense oligonucleotides, blocking antibody, fusion quantification assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP plus two independent inhibition strategies (antisense + antibody) with quantitative fusion readout\",\n      \"pmids\": [\"15574885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"After furin cleavage of the ADAM12-S prodomain in the trans-Golgi, the ~25 kDa prodomain remains non-covalently associated with the ~68 kDa mature ADAM12-S. Electron microscopy revealed a compact clover-like four-domain structure for the full-length ADAM12-S molecule.\",\n      \"method\": \"Domain-specific antisera, immunoprecipitation, Western blot of serum and recombinant ADAM12, negative-stain electron microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural visualization by EM plus biochemical co-precipitation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16455653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ADAM12 interacts with TGF-β type II receptor (TβRII) and facilitates TGF-β signaling (Smad2 phosphorylation, Smad2/Smad4 association, transcriptional activation) independently of its protease activity; ADAM12 promotes accumulation of TβRII in early endosomes and stabilizes TβRII by suppressing its association with Smad7.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative and catalytically inactive ADAM12 mutants, endosomal fractionation, Smad reporter assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP plus protease-dead mutant plus endosomal fractionation plus transcriptional reporter, multiple orthogonal methods in a focused study\",\n      \"pmids\": [\"17620406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Human ADAM12-S catalytic properties: cleavage of S-carboxymethylated transferrin at multiple sites; noncatalytic C-terminal domains regulate activity; N-TIMP-3 inhibits ADAM12-S with low nanomolar Ki; TIMP-2 inhibits with slightly lower affinity; TIMP-1 is a much weaker inhibitor; NaCl inhibits ADAM12.\",\n      \"method\": \"In vitro enzymatic assay with recombinant ADAM12-S and domain deletion mutants, kinetic analysis, N-terminal sequencing\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with recombinant protein and domain mutants, kinetic parameters established\",\n      \"pmids\": [\"18081311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Heparan sulfate and heparin regulate ADAM12 activity through a prodomain/catalytic domain cationic molecular switch; endogenous cell surface proteoglycans also regulate this switch; human heparanase can promote ADAM12 sheddase activity at the cell surface by cleaving inhibitory heparan sulfate.\",\n      \"method\": \"In vitro sheddase assays, heparanase treatment, cell-based shedding assay, polyanion treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic reconstitution plus cell-based shedding assay with heparanase functional experiments\",\n      \"pmids\": [\"18801731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RACK1 (receptor for activated PKC) was identified as an ADAM12 interacting protein by yeast two-hybrid; PKC-dependent phorbol ester treatment enhances co-immunoprecipitation of a ternary RACK1/ADAM12/PKC complex and ADAM12 membrane translocation; siRNA knockdown of RACK1 diminishes PMA-dependent ADAM12 membrane translocation in hepatic stellate cells.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, subcellular fractionation, phorbol ester stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — yeast two-hybrid plus co-IP of ternary complex plus siRNA functional validation with fractionation readout\",\n      \"pmids\": [\"18621736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The disintegrin and cysteine-rich (DC) domains of ADAM12 bind integrin α7β1; α7X1 and α7X2 splice variants support equal adhesion to DC domain; adhesion to DC differs from laminin in Mn2+ requirements and does not trigger FAK Tyr397 phosphorylation or efficient spreading.\",\n      \"method\": \"Affinity column pulldown, cell adhesion assay, blocking antibody, FAK phosphorylation Western blot\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — affinity pulldown plus functional adhesion assay plus blocking antibody, single lab\",\n      \"pmids\": [\"15242759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The intact extracellular domain of ADAM12 (metalloprotease + disintegrin/cysteine-rich domains together) supports myoblast-specific adhesion and spreading not mediated by β1 integrins or proteoglycans, and inhibits differentiation (reduces p21 and myogenin); neither the metalloprotease domain nor the disintegrin/cysteine-rich fragment alone recapitulates this activity, indicating cooperative interdomain interaction.\",\n      \"method\": \"Recombinant domain production in Drosophila S2 cells, cell adhesion/spreading assays, far-UV circular dichroism, Western blot for differentiation markers\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted domain interactions with structural (CD) and functional (adhesion, differentiation) validation, systematic domain dissection\",\n      \"pmids\": [\"15849365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In cell adhesion assays, α9β1 integrin is the primary receptor for ADAM12; when α9β1 is absent, other β1 family integrins can serve as alternate receptors; the disintegrin domain alone supports only α9 integrin-dependent attachment, while full-length ADAM12 supports additional integrin-mediated attachment; cell spreading requires PI3K activity.\",\n      \"method\": \"Cell adhesion assays with recombinant ADAM12 fragments and mutants, blocking antibodies, PI3K inhibitor\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic domain fragments plus mutant plus pharmacological inhibition, single lab\",\n      \"pmids\": [\"16061220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TGF-β1-induced ADAM12 expression in hepatic stellate cells requires both the PI3K/Frap-mTOR/p70S6K and MEK/ERK pathways; rapamycin (mTOR inhibitor) blocks p70S6K phosphorylation and ADAM12 induction, while basal ADAM12 expression depends on PI3K/Akt/GSK-3 signaling.\",\n      \"method\": \"PI3K inhibitor (LY294002), MEK inhibitor (UO126), rapamycin treatment, Western blot for phospho-p70S6K\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological pathway dissection with multiple inhibitors targeting distinct nodes, single lab\",\n      \"pmids\": [\"16139919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ADAM12-S transgenic mice exhibit increased longitudinal bone growth through modulation of chondrocyte proliferation and maturation; mice expressing a truncated metalloprotease-deficient ADAM12-S showed no bone length alterations, indicating protease activity is required. ADAM12-S inhibits chondrocyte adhesion to fibronectin and collagen type II in vitro.\",\n      \"method\": \"Transgenic mouse bone length measurement, histology, BrdU incorporation, metalloprotease-deficient truncation mutant, in vitro chondrocyte adhesion assay\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic gain-of-function with catalytic mutant rescue experiment plus in vitro adhesion assay, multiple orthogonal readouts\",\n      \"pmids\": [\"16869727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ADAM12-L co-localizes with c-Src at actin-rich peripheral structures; two separate c-Src binding sites in the ADAM12-L cytoplasmic tail interact with the SH3 domain of c-Src; c-Src kinase activity induces ADAM12-L tyrosine phosphorylation; the association is stabilized when c-Src kinase activity is disrupted; ADAM12-L enhances Src kinase activity upon integrin engagement.\",\n      \"method\": \"Co-immunoprecipitation, co-localization imaging, SH3 domain binding assay, kinase-inactive c-Src mutant, tyrosine phosphorylation Western blot\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus domain binding site mapping plus kinase-dead mutant plus kinase activity assay, multiple orthogonal methods\",\n      \"pmids\": [\"19769962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MMP-7 controls transcription of ADAM12, forming a novel MMP-7/ADAM12 signaling axis in agonist-induced hypertension and cardiac hypertrophy; MMP-7 knockdown attenuates hypertension, inhibits ADAM12 overexpression, and prevents cardiac hypertrophy in mouse models.\",\n      \"method\": \"RNAi knockdown, antisense oligodeoxynucleotides, MMP-7 gene knockout, quantitative RT-PCR, rodent hypertension models\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three complementary approaches (pharmacological, RNAi, knockout) in vivo, single lab\",\n      \"pmids\": [\"19398663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Antibody ligation of ADAM12 induces formation of invadopodia clusters with ECM-degrading capacity in cells expressing αvβ3 integrin and active c-Src; this requires an intact c-Src interaction site in the ADAM12 cytoplasmic domain but is independent of ADAM12 catalytic activity; caveolin-1 and MMP14/MT1-MMP localize in these clusters; ADAM12-mediated HB-EGF shedding occurs within invadopodia.\",\n      \"method\": \"Antibody ligation, invadopodia formation assay, domain mutants (cytoplasmic tail deletion, catalytic mutant), cholesterol depletion, ectodomain shedding assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mutant dissection plus pharmacological manipulation plus functional shedding assay, multiple orthogonal methods\",\n      \"pmids\": [\"20951132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TGF-β1 induces ADAM12 mRNA and protein in a Smad2/Smad3-dependent manner; SnoN, a negative regulator of TGF-β signaling, acts as a repressor of ADAM12 gene expression; SnoN overexpression reduces ADAM12 induction, while SnoN shRNA knockdown enhances it.\",\n      \"method\": \"Smad2/3-dependent reporter, shRNA knockdown of SnoN, overexpression of SnoN, Western blot, qRT-PCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — both gain- and loss-of-function for SnoN with Smad-pathway validation, single lab\",\n      \"pmids\": [\"20457602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ADAM12 selectively inhibits ADAM12 activity; engineered N-TIMP-2 (with AB-loop removed) shows increased affinity for ADAM12 compared to TACE/ADAM17; N-TIMP-2 and its mutants inhibit the transmembrane ADAM12-L in cell-based HB-EGF shedding assays, revealing distinctive structural requirements for ADAM12 inhibition.\",\n      \"method\": \"Kinetic analysis with fluorescent peptide substrate, N-TIMP-2 mutagenesis, cell-based EGF shedding assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetic assay plus mutagenesis plus cell-based functional validation in one study\",\n      \"pmids\": [\"20533908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Notch signaling up-regulates ADAM12 expression in a CSL-dependent, IκB kinase-dependent manner; the microRNA-29 family mediates this effect by being downregulated by Notch, relieving repression of the ADAM12 3'UTR; in human cells, Notch specifically up-regulates ADAM12-L (which has a divergent 3'UTR containing the miR-29 site) but not ADAM12-S.\",\n      \"method\": \"Constitutively active Notch1 transfection, CSL reporter, IKK inhibitor, miR-29 target site validation, co-culture with Notch ligand-expressing cells, qRT-PCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple cell systems plus genetic and pharmacological inhibition plus miRNA target validation, multiple orthogonal methods\",\n      \"pmids\": [\"21518768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Breast cancer-associated ADAM12 somatic mutations D301H and G479E (involving conserved residues) cause retention of ADAM12 in the ER, block cell surface trafficking, prevent Delta-like 1 shedding, and exert dominant-negative effects on wild-type ADAM12 processing.\",\n      \"method\": \"Mutagenesis, cell surface biotinylation, immunofluorescence, ectodomain shedding assay, dominant-negative co-expression\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-specific mutations with trafficking, surface expression, and functional shedding readouts in multiple cell lines\",\n      \"pmids\": [\"18241035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Notch signaling increases ADAM12 metalloprotease levels and activity in hypoxia in a Notch-dependent manner, leading to increased HB-EGF shedding, EGFR activation, and invadopodia formation; thus Notch-ADAM12-HB-EGF-EGFR constitutes a hypoxia-driven invasion signaling axis.\",\n      \"method\": \"Notch pathway inhibition, ADAM12 knockdown/overexpression, ectodomain shedding assay, invadopodia formation assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic pathway dissection with KD and OE experiments and functional shedding/invasion assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23589494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADAM12 redistributes endogenous MMP-14 to the cell surface and promotes its activation; subsequent gelatin degradation and reduced apoptosis depend on MMP-14 activity and cell surface αVβ3 integrin localization but not on ADAM12 catalytic activity or its cytoplasmic tail; a ternary ADAM12/αVβ3/MMP-14 complex is proposed based on co-localization and antibody inhibition.\",\n      \"method\": \"Co-localization, MMP-14 activity assays, specific monoclonal antibodies, domain mutants (catalytic-dead, cytoplasmic tail deletion), orthotopic implantation, Western blot for activated MMP-14\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain mutant dissection plus antibody inhibition plus in vivo tumor model with multiple orthogonal methods\",\n      \"pmids\": [\"24006261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADAM12 was identified by yeast two-hybrid as an EphA1-binding partner; ADAM12 enhances ephrin-A1 cleavage in response to TGF-β1 in primary tumors, releasing soluble ephrin-A1 into the serum that disrupts EphA1/ephrin-A1-mediated cell adhesion in the lungs, causing hyperpermeability and facilitating lung metastasis.\",\n      \"method\": \"Yeast two-hybrid, ectodomain cleavage assay (TGF-β1 stimulation), neutralizing antibody against soluble ephrin-A1, lung metastasis model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus functional cleavage assay plus in vivo neutralization, single lab\",\n      \"pmids\": [\"23686306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADAM12 screens positive for shedding of five new substrates: Kitl1, VE-cadherin, Flk-1, Tie-2, and VCAM-1; siRNA knockdown of ADAM12 reduces cytokine-induced VE-cadherin shedding in endothelial cells.\",\n      \"method\": \"Ectodomain shedding screen, siRNA knockdown, Western blot of shed forms\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — shedding screen plus siRNA knockdown with defined substrate readouts, single lab\",\n      \"pmids\": [\"23458101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ILK (integrin-linked kinase) was identified as a new ADAM12L interacting protein; ADAM12L co-immunoprecipitates with ILK via its cytoplasmic tail; in hepatic stellate cells, ADAM12L and ILK redistribute to focal adhesions upon β1 integrin stimulation; ADAM12L upregulation activates Akt Ser-473 phosphorylation via PI3K/ILK in a protease-independent manner; ILK depletion abolishes this survival signal.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of ILK and ADAM12L, cytoplasmic tail deletion mutant, Akt phosphorylation Western blot, ILK kinase activity assay from immunoprecipitates\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus domain mutant plus ILK activity assay plus siRNA rescue experiments with Akt readout\",\n      \"pmids\": [\"22767580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADAM12 mediates ectodomain shedding of E-cadherin to promote trophoblast fusion; siRNA knockdown of ADAM12 impedes spontaneous cytotrophoblast fusion; overexpression of ADAM12S potentiates fusion in Bewo cells; E-cadherin is identified as a novel ADAM12 substrate; ADAM12 expression is under transcriptional control of protein kinase A.\",\n      \"method\": \"siRNA knockdown, ADAM12S overexpression, E-cadherin shedding assay, PKA inhibitor, two distinct trophoblast fusion models\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function plus gain-of-function plus substrate identification, two independent cell models\",\n      \"pmids\": [\"25909890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADAM12L (but not ADAM12S) induces EMT in MCF10A cells independently of proteolytic activity but requiring the cytoplasmic tail; ADAM12L-dependent EMT involves increased phosphorylation of Smad3, Akt, and ERK; TGF-β receptor or ERK inhibition reverses ADAM12L-induced mesenchymal phenotype.\",\n      \"method\": \"ADAM12L overexpression (catalytic mutant, cytoplasmic tail deletion), Western blot for EMT markers and phospho-signaling, TGF-β receptor inhibitor, ERK inhibitor\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic domain mutant analysis plus pharmacological rescue in a defined cell model with multiple EMT/signaling readouts\",\n      \"pmids\": [\"26407179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-29b/c and miR-200b/c directly target the ADAM12-L 3'UTR (but not ADAM12-S 3'UTR) to reduce ADAM12-L mRNA and protein levels; mutation of miR-29b/c or miR-200b/c target sequences in the ADAM12-L 3'UTR abrogates this repression; miR-30b/d did not show consistent effects.\",\n      \"method\": \"miRNA mimic transfection, 3'UTR luciferase reporter assay with target site mutations, metabolic labeling for translation rate, miRNA hairpin inhibitors, qRT-PCR\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — luciferase reporter with target site mutagenesis plus endogenous miRNA inhibitor experiments plus metabolic labeling, multiple orthogonal methods\",\n      \"pmids\": [\"25886595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADAM12 expression in endothelial cells regulates the neural vascular barrier under hypoxia by mediating shedding of claudin-5 (tight junction molecule); inhibition of ADAM12 (or ADAM17) metalloprotease activity rescues claudin-5 membrane localization and barrier function both in vitro and in vivo under hypoxia.\",\n      \"method\": \"Metalloprotease inhibition, ADAM12 and ADAM17 specific knockdown, in vitro barrier assay (TEER), in vivo neural vascular barrier assessment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gene-specific knockdown plus pharmacological inhibition with functional barrier readouts in vitro and in vivo, single lab\",\n      \"pmids\": [\"26242473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ADAM12 protease activity and the FISH adapter protein mediate Aβ-induced neuronal death; expression of a protease-deficient ADAM12 mutant blocks Aβ-induced neuronal death; the C-terminal FISH fragment induces cell death that requires ADAM12 metalloprotease activity; Aβ treatment and toxic FISH fragment both induce accumulation of an ADAM12 N-terminal cleavage product, indicating ADAM12 sheddase activation.\",\n      \"method\": \"Protease-deficient ADAM12 mutant expression, FISH domain truncation expression, conditioned medium analysis for ADAM12 cleavage products, neuronal cell death assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protease-dead mutant rescue plus substrate cleavage product detection, single lab with functional and biochemical readouts\",\n      \"pmids\": [\"15710903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Twist1 transcription factor induces ADAM12 expression; ADAM12 knockdown blocks Twist1-induced tumor invasion and metastasis in breast xenografts without affecting primary tumor formation; both the disintegrin and metalloproteinase domains are required for invadopodia function, while the metalloproteinase domain is dispensable for focal adhesion turnover; ADAM12 knockdown inhibits focal adhesion turnover (shown by live-imaging).\",\n      \"method\": \"siRNA/shRNA knockdown, 3D organoid invasion assay, xenograft metastasis model, live-imaging of focal adhesion turnover, domain mutant analysis\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain mutant dissection plus live imaging plus in vivo xenograft, multiple orthogonal methods across in vitro and in vivo settings\",\n      \"pmids\": [\"28468988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ADAM12 interacts with basigin and cleaves it in the juxtamembrane region; ADAM12 overexpression increases ectodomain shedding of an alkaline phosphatase-tagged basigin reporter; CRISPR/Cas9 knockout of ADAM12 reduces basigin shedding, which is rescued by ADAM12 re-expression; ADAM12-generated basigin ectodomain fragments were detected in conditioned media and serum samples.\",\n      \"method\": \"Co-immunoprecipitation, alkaline phosphatase shedding reporter, CRISPR/Cas9 knockout, rescue by re-expression, Western blot for endogenous ectodomain fragments in conditioned media and serum\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR knockout plus rescue plus shedding reporter plus endogenous substrate fragment detection, multiple orthogonal methods\",\n      \"pmids\": [\"31013576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hypoxia activates HIF-dependent ADAM12 expression in breast cancer cells, which mediates increased HB-EGF ectodomain shedding, EGFR activation, and FAK phosphorylation; ADAM12 inhibition decreased hypoxia-induced cell migration/invasion in vitro and dramatically impaired lung metastasis in orthotopic mouse models.\",\n      \"method\": \"HIF knockdown/overexpression, ADAM12 siRNA, ectodomain shedding assay, EGFR/FAK phosphorylation Western blot, orthotopic breast cancer metastasis model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic pathway dissection (HIF→ADAM12→HB-EGF→EGFR→FAK) in vitro with in vivo metastasis validation, multiple orthogonal methods\",\n      \"pmids\": [\"33952697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ADAM12 acts as a T-cell costimulatory molecule expressed on naïve T cells; ADAM12 Fab antibody stimulation amplifies TCR signaling to promote T-bet-mediated IFNγ production and Th1 differentiation; genomic ADAM12 loss or T-cell ADAM12 knockdown selectively diminishes T-bet and IFNγ in Th1 cells without affecting Th17 cells; ADAM12-/- mice show profoundly reduced Th1-mediated neuroinflammation in EAE.\",\n      \"method\": \"Monoclonal ADAM12 Fab antibody stimulation, ADAM12 knockout mice, shRNA knockdown in T cells, EAE model, transcriptomic profiling, IFNγ/T-bet measurement\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — antibody functional assay plus KO mice plus shRNA with multiple lineage-specific and in vivo readouts\",\n      \"pmids\": [\"32572163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FLRG (follistatin-related gene) directly interacts with the cysteine-rich domain of ADAM12 as identified by yeast two-hybrid; FLRG inhibits osteoclast differentiation from murine spleen cells and RAW264.7 macrophages, reducing osteoclast numbers and nuclei count.\",\n      \"method\": \"Yeast two-hybrid, osteoclast differentiation assay with recombinant FLRG, RANKL/M-CSF stimulation\",\n      \"journal\": \"Biology of the cell\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid without biochemical co-IP validation; functional assay with recombinant FLRG tests FLRG function rather than directly validating ADAM12 role\",\n      \"pmids\": [\"15574124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TGF-β induces ADAM12 gene expression through PI3K/Frap-mTOR/p70S6K and MEK/ERK pathways in hepatic stellate cells. Inhibition of p70S6K by rapamycin blocks TGF-β-dependent ADAM12 expression.\",\n      \"method\": \"Rapamycin, LY294002, UO126 treatment; p70S6K phosphorylation Western blot; TGF-β1 stimulation\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — three pharmacological inhibitors targeting distinct pathway nodes with phospho-signaling readouts, single lab\",\n      \"pmids\": [\"16139919\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADAM12 is a multidomain transmembrane or secreted metalloprotease (ADAM12-L and ADAM12-S isoforms) that undergoes furin-mediated prodomain cleavage in the trans-Golgi to yield a constitutively active ~90 kDa mature form whose cell-surface translocation is regulated by PKCε (via RACK1 and direct PKCε binding); the retained prodomain forms a non-covalent clover-like structure with the mature enzyme and its sheddase activity is allosterically regulated by a heparan sulfate/prodomain molecular switch; at the cell surface ADAM12 sheds multiple EGFR ligands (notably HB-EGF), E-cadherin, basigin, ephrin-A1, VE-cadherin, Tie-2, and VCAM-1 to drive EGFR/ERK/FAK signaling, and its shedding activity is inhibited by TIMP-3 and engineered N-TIMP-2 but not TIMP-1; ADAM12 also interacts non-catalytically with TGF-β type II receptor to promote Smad2 signaling and TβRII endosomal trafficking, with ILK via its cytoplasmic tail to activate PI3K/Akt survival signaling, with c-Src (via cytoplasmic SH3-binding sites) to regulate Src kinase activity and subcellular redistribution, and with integrins α9β1, α7β1, and αvβ3 via its disintegrin/cysteine-rich domains to modulate cell adhesion, actin cytoskeleton organization, and focal adhesion turnover; upstream, ADAM12 expression is transcriptionally induced by TGF-β1 (via Smad2/3, derepression of SnoN, and PI3K/mTOR/p70S6K), Notch (via CSL/IKK, partly through suppression of miR-29), HIF (in hypoxia), Twist1, and HER2/PI3K/AKT, and post-transcriptionally repressed by miR-29 and miR-200 families targeting the ADAM12-L 3'UTR; together these activities enable ADAM12 to regulate myoblast fusion, adipocyte differentiation, chondrocyte proliferation, trophoblast invasion and fusion, Th1 T-cell costimulation, and tumor invasion/metastasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADAM12 is a multidomain metalloprotease (transmembrane ADAM12-L and secreted ADAM12-S isoforms) that couples regulated ectodomain shedding to integrin- and adapter-mediated signaling to drive cell fusion, differentiation, adhesion remodeling, and tumor invasion [#0, #10, #38]. The enzyme is N-glycosylated in the ER and proteolytically matured in the trans-Golgi to an ~90 kDa form; its cytoplasmic domain governs ER exit and the prodomain α-helix is required for folding and processing, after which the cleaved prodomain remains non-covalently bound to mature enzyme in a compact clover-like four-domain structure [#3, #11]. Mature ADAM12 sheds a broad substrate set — HB-EGF, E-cadherin, basigin, ephrin-A1, claudin-5, and endothelial junction/receptor molecules including VE-cadherin and Tie-2 — to transactivate EGFR and remodel cell–cell barriers [#0, #33, #39, #30, #36, #31]. Catalytic activity is intrinsically inhibitable by N-TIMP-3 and TIMP-2 (but weakly by TIMP-1) and is allosterically gated by a heparan sulfate/prodomain cationic molecular switch that heparanase can relieve at the cell surface [#13, #14]. Surface delivery of the active enzyme is controlled by PKCε acting through direct binding and the RACK1 scaffold, with PACSIN3 coupling the cytoplasmic tail to shedding [#8, #15, #6]. Beyond proteolysis, ADAM12 signals non-catalytically: it binds TβRII to promote Smad2 signaling and receptor endosomal trafficking [#12], engages ILK through its cytoplasmic tail to activate PI3K/Akt survival signaling [#32], associates with c-Src and αvβ3 integrin to assemble MMP-14-containing invadopodia and drive focal adhesion turnover [#21, #23, #29, #38], and uses its disintegrin/cysteine-rich domains to bind integrins α9β1 and α7β1 and syndecan-4, organizing actin, focal adhesions, and cell spreading [#1, #16, #4]. These activities underpin myoblast cell-cycle exit and fusion, chondrocyte proliferation during bone growth, trophoblast fusion, and Th1 T-cell costimulation, and they are amplified in cancer through hypoxia/HIF-, Notch-, Twist1-, and TGF-β/Smad-driven induction with post-transcriptional repression by miR-29 and miR-200 on the ADAM12-L 3'UTR [#9, #10, #20, #33, #41, #40, #28, #38, #24, #35].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that ADAM12's disintegrin domain mediates integrin-based cell-cell interaction, defining a non-proteolytic adhesive function distinct from canonical RGD-dependent binding.\",\n      \"evidence\": \"Recombinant disintegrin domain binding and cell adhesion assays with integrin α9β1\",\n      \"pmids\": [\"10944520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map the binding interface residues\", \"In vivo relevance of α9β1 engagement not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified ADAM12 as a specific physiological HB-EGF sheddase driving EGFR transactivation, linking the protease to GPCR-evoked cardiac hypertrophy in vivo.\",\n      \"evidence\": \"Dominant-negative expression, direct inhibitor binding, mouse cardiac hypertrophy model\",\n      \"pmids\": [\"11786904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate repertoire beyond HB-EGF not addressed\", \"Did not resolve how shedding is spatially restricted\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the biosynthetic route of ADAM12, showing furin-type trans-Golgi maturation and that the cytoplasmic tail and prodomain α-helix control trafficking and folding.\",\n      \"evidence\": \"Prodomain/cytoplasmic mutagenesis, surface biotinylation, subcellular fractionation\",\n      \"pmids\": [\"12000744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the maturation protease directly\", \"Trafficking machinery for ER exit not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Connected ADAM12 to outside-in adhesion signaling by showing syndecan-4 acts as a receptor triggering β1-integrin-dependent spreading via PKCα/RhoA.\",\n      \"evidence\": \"Co-IP, PKC inhibitors, mutant syndecan-4, activated β1 integrin staining\",\n      \"pmids\": [\"12509413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct syndecan-4/ADAM12 binding stoichiometry not resolved\", \"Link to proteolytic function unaddressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed ADAM12 controls myoblast fate, with expression promoting cell-cycle arrest and quiescence markers via its disintegrin/cytoplasmic regions rather than its protease domain.\",\n      \"evidence\": \"siRNA, domain-deletion overexpression, cell cycle analysis in C2C12\",\n      \"pmids\": [\"12972593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating the non-proteolytic effect not defined here\", \"Downstream effectors of p130/p27 induction unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Revealed that surface ADAM12 antagonizes β1 integrin function in preadipocytes, remodeling actin and promoting apoptosis rescuable by integrin activation.\",\n      \"evidence\": \"Co-IP, retroviral expression, adhesion assays, integrin-activating antibody rescue\",\n      \"pmids\": [\"12915587\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of integrin impairment not resolved\", \"Relationship to adipocyte differentiation in vivo untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified PACSIN3 as a cytoplasmic-tail SH3 partner that couples ADAM12 to regulated proHB-EGF shedding.\",\n      \"evidence\": \"Yeast two-hybrid, GST pulldown, co-IP, siRNA, shedding assay\",\n      \"pmids\": [\"12952982\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which PACSIN3 enhances shedding not defined\", \"Endogenous physiological context limited\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Placed ADAM12 transcription downstream of TGF-β via PI3K and MEK/ERK during hepatic stellate cell activation.\",\n      \"evidence\": \"Northern blot with PI3K and MEK inhibitors in HSC culture\",\n      \"pmids\": [\"12717386\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor-based pharmacology only, no genetic confirmation\", \"Transcription factors not identified at this stage\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed PKCε directly drives ADAM12 surface translocation, defining a kinase-dependent regulatory step controlling protease availability.\",\n      \"evidence\": \"Co-IP, PMA, myristoylated and kinase-dead PKCε mutants, surface immunostaining\",\n      \"pmids\": [\"15364951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation site mediating translocation not mapped\", \"Did not yet implicate a scaffold\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated ADAM12 overexpression and HB-EGF shedding promote glioblastoma proliferation, extending the sheddase axis to tumor growth.\",\n      \"evidence\": \"qRT-PCR, in situ hybridization, ADAM inhibitor treatment of tumor tissue\",\n      \"pmids\": [\"15509542\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlative tissue data with non-specific ADAM inhibitor\", \"ADAM12-specific requirement not genetically isolated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Quantified ADAM12/α9β1 integrin interaction as a major driver of human myoblast fusion, particularly large myotube formation.\",\n      \"evidence\": \"Co-IP, antisense, anti-α9β1 blocking antibody, fusion quantification\",\n      \"pmids\": [\"15574885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The fusion machinery downstream of α9β1 engagement not defined\", \"Residual fusion (~50%) involves unidentified factors\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Expanded the integrin partner set by showing the disintegrin/cysteine-rich domains bind α7β1 with adhesion properties distinct from laminin.\",\n      \"evidence\": \"Affinity pulldown, adhesion assay, blocking antibody, FAK phospho-blot\",\n      \"pmids\": [\"15242759\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of α7β1 binding in vivo unclear\", \"Single-lab adhesion characterization\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined cooperative interdomain function, showing the intact extracellular region supports myoblast adhesion and inhibits differentiation in a manner no single domain reproduces.\",\n      \"evidence\": \"Recombinant domains from S2 cells, adhesion/spreading assays, CD spectroscopy, differentiation markers\",\n      \"pmids\": [\"15849365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The myoblast receptor for intact ectodomain not identified\", \"Structural basis of cooperativity not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Refined the integrin receptor hierarchy, establishing α9β1 as primary with alternate β1 integrins as backups and PI3K dependence for spreading.\",\n      \"evidence\": \"Adhesion assays with ADAM12 fragments/mutants, blocking antibodies, PI3K inhibitor\",\n      \"pmids\": [\"16061220\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab in vitro adhesion model\", \"Selectivity rules among β1 integrins not fully defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linked ADAM12 protease activity to Aβ-induced neuronal death through the FISH adapter, implicating sheddase activation in neurotoxicity.\",\n      \"evidence\": \"Protease-dead mutant, FISH truncation, cleavage-product detection, neuronal death assay\",\n      \"pmids\": [\"15710903\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relevant shed substrate driving death not identified\", \"Single-lab functional model\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Dissected the TGF-β-driven induction cascade, showing both PI3K/mTOR/p70S6K and MEK/ERK branches are required for ADAM12 expression.\",\n      \"evidence\": \"Rapamycin, LY294002, UO126, phospho-p70S6K blots in HSCs\",\n      \"pmids\": [\"16139919\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pharmacology-only with no genetic confirmation\", \"Transcription factor endpoints not identified here\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified FLRG as a cysteine-rich-domain partner linked to osteoclast differentiation, though the assay primarily tested FLRG rather than ADAM12.\",\n      \"evidence\": \"Yeast two-hybrid, osteoclast differentiation assay with recombinant FLRG\",\n      \"pmids\": [\"15574124\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Awaits biochemical co-IP validation of the interaction\", \"ADAM12's direct role in osteoclastogenesis not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated in vivo that ADAM12-S protease activity promotes longitudinal bone growth by modulating chondrocyte proliferation and adhesion.\",\n      \"evidence\": \"Transgenic mice, BrdU, catalytically dead truncation, chondrocyte adhesion assays\",\n      \"pmids\": [\"16869727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The chondrocyte substrate cleaved was not identified\", \"Mechanism of adhesion inhibition unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established the architecture of the mature/prodomain complex, showing retained non-covalent prodomain association and a compact clover-like structure.\",\n      \"evidence\": \"Domain-specific antisera, immunoprecipitation, negative-stain EM\",\n      \"pmids\": [\"16455653\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structure not obtained\", \"Functional role of retained prodomain in activity not defined here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed a protease-independent signaling role: ADAM12 binds TβRII to enhance Smad2 signaling and stabilize the receptor in endosomes by blocking Smad7.\",\n      \"evidence\": \"Co-IP, catalytically dead mutants, endosomal fractionation, Smad reporter\",\n      \"pmids\": [\"17620406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding interface on TβRII not mapped\", \"Generality across TGF-β-responsive cell types untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Characterized ADAM12-S catalytic mechanism, defined noncatalytic C-terminal regulation, and established the TIMP inhibition profile (N-TIMP-3 > TIMP-2 >> TIMP-1).\",\n      \"evidence\": \"In vitro kinetics with recombinant protein and domain mutants, N-terminal sequencing\",\n      \"pmids\": [\"18081311\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrate specificity not addressed\", \"Structural basis of TIMP selectivity unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Uncovered an allosteric heparan sulfate/prodomain cationic switch regulating sheddase activity, relieved by heparanase at the cell surface.\",\n      \"evidence\": \"In vitro sheddase assays, heparanase and polyanion treatment, cell-based shedding\",\n      \"pmids\": [\"18801731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch residues not fully mapped\", \"In vivo contribution of proteoglycan regulation untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified RACK1 as the scaffold assembling a RACK1/ADAM12/PKC ternary complex required for PKC-dependent membrane translocation.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP of ternary complex, siRNA, fractionation\",\n      \"pmids\": [\"18621736\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RACK1 binding site on ADAM12 not mapped\", \"Quantitative contribution to surface pool not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a reciprocal ADAM12-L/c-Src relationship in which two cytoplasmic SH3-binding sites recruit Src and ADAM12 enhances Src activity upon integrin engagement.\",\n      \"evidence\": \"Co-IP, colocalization, SH3 binding, kinase-dead Src, tyrosine phospho-blot\",\n      \"pmids\": [\"19769962\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of ADAM12 tyrosine phosphorylation unclear\", \"Downstream Src targets not defined here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified an MMP-7/ADAM12 transcriptional axis in agonist-induced hypertension and cardiac hypertrophy in vivo.\",\n      \"evidence\": \"RNAi, antisense, MMP-7 knockout, qRT-PCR, rodent hypertension models\",\n      \"pmids\": [\"19398663\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which MMP-7 controls ADAM12 transcription unresolved\", \"Single-lab in vivo correlation\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapped a non-catalytic invadopodia function requiring the c-Src interaction site, αvβ3 integrin, and recruitment of caveolin-1 and MT1-MMP.\",\n      \"evidence\": \"Antibody ligation, domain mutants, cholesterol depletion, shedding assay\",\n      \"pmids\": [\"20951132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological ligand triggering invadopodia not identified\", \"Order of assembly of the cluster unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed SnoN as a Smad-dependent repressor whose derepression mediates TGF-β1 induction of ADAM12, refining the transcriptional logic.\",\n      \"evidence\": \"Smad2/3 reporter, SnoN shRNA and overexpression, qRT-PCR, Western blot\",\n      \"pmids\": [\"20457602\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter occupancy not shown\", \"Single-lab cell context\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Engineered N-TIMP-2 variants showing ADAM12 has distinctive structural inhibition requirements, providing selective inhibitor leads.\",\n      \"evidence\": \"Kinetics with fluorescent peptide, N-TIMP-2 mutagenesis, cell-based shedding\",\n      \"pmids\": [\"20533908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-crystal structure of inhibitor complex not obtained\", \"In vivo efficacy untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a Notch→miR-29 circuit that isoform-selectively up-regulates ADAM12-L through CSL/IKK signaling and relief of 3'UTR repression.\",\n      \"evidence\": \"Active Notch1, CSL reporter, IKK inhibitor, miR-29 target validation, qRT-PCR\",\n      \"pmids\": [\"21518768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Notch target gene driving miR-29 suppression unclear\", \"Physiological setting limited\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed cancer-associated D301H/G479E mutations cause ER retention, block surface trafficking and Delta-like 1 shedding, and act dominant-negatively.\",\n      \"evidence\": \"Mutagenesis, surface biotinylation, immunofluorescence, shedding and dominant-negative assays\",\n      \"pmids\": [\"18241035\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of loss-of-trafficking in tumors untested\", \"Whether mutations are drivers unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified ILK as a cytoplasmic-tail partner mediating protease-independent PI3K/ILK/Akt survival signaling and focal adhesion redistribution.\",\n      \"evidence\": \"Co-IP, siRNA, tail-deletion mutant, Akt phospho-blot, ILK kinase assay\",\n      \"pmids\": [\"22767580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ILK binding motif on ADAM12 tail not mapped\", \"Survival phenotype in vivo untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated ADAM12 redistributes and activates MMP-14 within an αvβ3-dependent complex to degrade ECM and reduce apoptosis, independent of its own catalysis.\",\n      \"evidence\": \"Colocalization, MMP-14 activity assays, antibodies, domain mutants, orthotopic implantation\",\n      \"pmids\": [\"24006261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ternary complex not biochemically isolated\", \"Mechanism of MMP-14 activation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected ADAM12 to metastatic niche permeability via TGF-β1-stimulated ephrin-A1 shedding that disrupts EphA1/ephrin-A1 adhesion in lung.\",\n      \"evidence\": \"Yeast two-hybrid, cleavage assay, neutralizing antibody, lung metastasis model\",\n      \"pmids\": [\"23686306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ADAM12 cleavage of ephrin-A1 vs indirect not fully resolved\", \"Single-lab in vivo model\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Expanded the substrate repertoire to endothelial junction and receptor proteins (VE-cadherin, Tie-2, Flk-1, VCAM-1, Kitl1) in cytokine-driven shedding.\",\n      \"evidence\": \"Shedding screen, siRNA, Western blot of shed forms\",\n      \"pmids\": [\"23458101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect cleavage not distinguished for all hits\", \"Physiological context limited to endothelial cells\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established a hypoxia-driven Notch-ADAM12-HB-EGF-EGFR invasion axis controlling invadopodia formation.\",\n      \"evidence\": \"Notch inhibition, ADAM12 KD/OE, shedding and invadopodia assays\",\n      \"pmids\": [\"23589494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How hypoxia couples to Notch in this axis not fully resolved\", \"In vivo metastasis not tested in this study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified E-cadherin as a substrate whose shedding by ADAM12 promotes trophoblast fusion under PKA transcriptional control.\",\n      \"evidence\": \"siRNA, ADAM12S overexpression, E-cadherin shedding, PKA inhibitor, two fusion models\",\n      \"pmids\": [\"25909890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether E-cadherin shedding alone is sufficient for fusion unclear\", \"PKA-responsive promoter elements not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed ADAM12-L induces EMT via the cytoplasmic tail and Smad3/Akt/ERK signaling independent of protease activity, distinguishing isoform functions.\",\n      \"evidence\": \"Domain mutant overexpression, EMT/phospho-signaling blots, TβR and ERK inhibitors\",\n      \"pmids\": [\"26407179\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct tail effector linking to Smad3 unidentified\", \"Single cell-line model\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined isoform-selective post-transcriptional control, with miR-29b/c and miR-200b/c directly repressing the ADAM12-L 3'UTR.\",\n      \"evidence\": \"miRNA mimics, 3'UTR luciferase with mutated sites, metabolic labeling, miRNA inhibitors\",\n      \"pmids\": [\"25886595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative dominance of each miRNA in vivo unclear\", \"Upstream control of these miRNAs in tumors not addressed here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked ADAM12 to neural vascular barrier regulation via claudin-5 shedding under hypoxia.\",\n      \"evidence\": \"Metalloprotease inhibition, ADAM12/ADAM17 knockdown, TEER, in vivo barrier assay\",\n      \"pmids\": [\"26242473\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overlapping ADAM17 contribution not fully separated\", \"Direct claudin-5 cleavage not biochemically proven\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed ADAM12 downstream of Twist1 as a required effector of invasion/metastasis, with distinct domain requirements for invadopodia versus focal adhesion turnover.\",\n      \"evidence\": \"Knockdown, 3D organoid invasion, xenograft metastasis, live-imaging, domain mutants\",\n      \"pmids\": [\"28468988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Twist1 direct binding to ADAM12 promoter not shown\", \"Mechanism coupling domains to adhesion turnover unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Validated basigin as a direct ADAM12 substrate using CRISPR knockout and rescue, with detectable endogenous shed fragments.\",\n      \"evidence\": \"Co-IP, AP shedding reporter, CRISPR KO and re-expression, endogenous fragment detection\",\n      \"pmids\": [\"31013576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of basigin shedding not addressed\", \"Physiological trigger of cleavage unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed a non-classical immune role: ADAM12 is a T-cell costimulatory molecule selectively driving T-bet/IFNγ Th1 differentiation and Th1-mediated neuroinflammation.\",\n      \"evidence\": \"Fab antibody stimulation, knockout mice, shRNA, EAE model, transcriptomics\",\n      \"pmids\": [\"32572163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor/ligand mediating costimulation not identified\", \"Whether protease activity is involved unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established a HIF→ADAM12→HB-EGF→EGFR→FAK hypoxia axis driving breast cancer migration and lung metastasis in vivo.\",\n      \"evidence\": \"HIF KD/OE, ADAM12 siRNA, shedding and phospho-EGFR/FAK blots, orthotopic metastasis model\",\n      \"pmids\": [\"33952697\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct HIF binding to ADAM12 promoter not shown here\", \"Contribution of other shed substrates to metastasis unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse non-catalytic scaffolding functions (TβRII, ILK, c-Src, integrins) are integrated with regulated proteolysis to produce context-specific outputs, and the receptors mediating ADAM12's adhesive and immune-costimulatory roles, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of the active enzyme-prodomain complex with bound substrate\", \"Receptor mediating T-cell costimulation unidentified\", \"Coordination between shedding and adapter signaling in a single cell context not reconstituted\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 13, 33, 39, 31]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 13, 14]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [1, 4, 16, 10]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [4, 5, 21]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [12, 41]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [12, 32, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 5, 8, 23]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [3, 27]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [3, 11]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [11, 30, 39]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [4, 5, 21, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 12, 32, 21, 40]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 28, 38, 40, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9, 10, 20, 33]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 3, 13, 33, 39]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [4, 16, 20, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [41]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [24, 26, 35, 38]}\n    ],\n    \"complexes\": [\n      \"RACK1/ADAM12/PKCε ternary complex\",\n      \"ADAM12/αvβ3/MMP-14 invadopodial complex\"\n    ],\n    \"partners\": [\n      \"ITGA9\",\n      \"PKCε\",\n      \"RACK1\",\n      \"PACSIN3\",\n      \"TGFBR2\",\n      \"ILK\",\n      \"SRC\",\n      \"SDC4\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}